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Staphylococcus aureus is a major human pathogen and a global public 
health issue. It is considered an opportunistic pathogen as it asymptomatically 
colonizes its host, but can occasionally cause diseases that range in severity from 
relatively minor skin and soft tissue infections (SSTI) to life-threatening cases of 
pneumonia and endocarditis. There is a critical need to better understand 
mechanisms that lead to the evolution, resistance, and severity of S. aureus 
infections. Bacterial whole genome sequencing (WGS) techniques have offered 
new insights into S. aureus genomic populations and have the potential to predict 
antimicrobial resistance and infection severity. This study applied WGS 1) to 
describe the diversity and distribution of resistance mechanisms among 
community-associated S. aureus isolates, and 2) to identify S. aureus genetic 
signatures associated with SSTI isolates and derive a predictive risk model. WGS 
was performed on S. aureus isolates from patients within 14 primary care clinics 
in the South Texas Ambulatory Research Network from 2007 to 2015. The 
bacterial genomes were compared to a reference genome, FPR3757 (USA300 
 vii 
strain) to identify single nucleotide polymorphisms (SNPs). Phylogenetic analyses 
were conducted using concatenated SNP nucleotides in the core genomes. In the 
first study, the resistome was assembled by identifying antimicrobial resistance 
determinants related to the phenotypically derived antibiogram. The findings of this 
study identified that multidrug-resistant S. aureus isolates have emerged in the 
South Texas community; approximately one-third were multidrug-resistant. There 
was an increasing resistance pattern to fluoroquinolones. Furthermore, the 
genotype demonstrated to be highly predictive of antimicrobial resistance (very 
major error rate=0% and major error rate=1.4%). These findings highlight the 
genomic diversity of S. aureus strains in the South Texas community and 
demonstrate the utility of next generation sequencing to define the diversity and 
distribution of resistance mechanisms within S. aureus. Further work to explore 
antimicrobial selective pressures is needed. The second study utilized a bacterial 
genome-wide association study to identify specific variants associated with S. 
aureus pathogenicity. This study revealed the heterogeneity of S. aureus SSTI and 
nasal colonization isolates and identified potentially novel pathogenic 
mechanisms. 
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 1 
CHAPTER ONE 
Staphylococcus aureus infection epidemiology 
 
Introduction to Staphylococcus aureus infections 
Staphylococcus aureus is a Gram-positive cocci bacterium known to cause 
significant morbidity and mortality. It typically exists as a commensal bacterium, 
colonizing approximately one-third of the U.S. population. S. aureus is an 
opportunistic pathogen, having the ability to cause a wide range of infectious 
syndromes in humans, from relatively minor skin infections to more severe life-
threatening infections such as sepsis and endocarditis. It is a highly adaptive 
bacterium capable of producing a wide array of virulence factors and resistance 
mechanisms. These features allow S. aureus to evade host defense mechanisms, 
cause rapid dissemination, and acquire antimicrobial resistance. S. aureus 
represents a major threat to the American public. There has never been a more 
crucial time to develop interventions to prevent and effectively treat S. aureus 
infections.   
 
 
 
 
 
 
 2 
Evolution of S. aureus 
Staphylococcus was first discovered in 1880 by the surgeon Sir Alexander 
Ogston in Aberdeen, Scotland. He observed grape-like clusters of bacteria under 
the microscope, which was therefore named Staphylococcus from the Greek 
expression “a bunch of grapes”. A few years later, Friedrich Rosenbach gave its 
formal nomenclature, Staphylococcus aureus for its characteristic “gold” 
pigmented appearance of colonies.1  
Since its discovery, S. aureus has demonstrated a remarkable ability to 
evolve and acquire resistance to almost any antibiotic. Infections caused by 
antibiotic resistant S. aureus have reached epidemic proportions globally. 
Beginning in the 1940s, several “waves of resistance” by S. aureus have occurred 
(Figure 1.1).2 The first wave was described after the initial use of the first known 
antibiotic, penicillin, with the emergence of penicillinase-producing S. aureus 
infections. These infections were primarily caused by a S. aureus clone known as 
phage-type 80/81.3-5 After the introduction of methicillin, the pandemic phage-type 
80/81 largely declined. However, the prevalence of different penicillinase-
producing S. aureus strains continues to remain high.6 The second wave of 
resistance began shortly after the use of methicillin. In 1961, the first case of 
methicillin-resistant S. aureus (MRSA) was reported followed by the first MRSA 
outbreak in 1963.7 
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Figure 1.1 Evolution of S aureus 
 
 
For decades, MRSA infections were limited to hospitals, and affected mostly 
older patients with comorbid conditions and those exposed to the health care 
setting. However, in the last three decades, there has been a dramatic rise of 
MRSA infections in the community setting, known as community-associated 
methicillin-resistant S. aureus (CA-MRSA). These CA-MRSA strains have rapidly 
disseminated and are endemic in most areas of the U.S. In contrast to health care-
associated MRSA (HA-MRSA), CA-MRSA strains most commonly affect healthy 
individuals without traditional risk factors or health care exposures.8-10 A timeline 
of the emergence of CA-MRSA infections is depicted in Table 1.1. Among these 
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reports, the most common manifestation of CA-MRSA is skin and soft tissue 
infections (SSTIs). 
Table 1.1 Timeline of the emergence of CA-MRSA infections11-18 
Years Report description 
1980-1981 First report of CA-MRSA in Detroit, MI 
1989-1998 Outbreaks in geographically separate regions; Australia, 
Papua New Guinea, Turkey, New Zealand 
1993-1994 Outbreak in a high school wrestling team in Vermont 
1997 Outbreak in Native American population in Midwest U.S. 
1997-1999 4 pediatric deaths due to septic shock caused by CA-MRSA 
1997-2003 Outbreaks in prison populations in Los Angeles and San 
Francisco 
1998 Outbreak in a rugby team in Great Britain 
2002-2003 Outbreaks reported in HIV+ people and men who have sex 
with men 
2003 Outbreak among athletes of the St. Louis Rams 
professional football team 
CA-MRSA=community-associated methicillin resistant S. aureus; HIV=human 
immunodeficiency virus 
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Classification of S. aureus  
Classification of S. aureus, particularly MRSA, has traditionally been 
classified into HA-MRSA and CA-MRSA. However, the HA-MRSA and CA-MRSA 
classifications are no longer distinct.19-21 Recent surveillance has shown that HA-
MRSA can spread to community contacts and CA-MRSA is becoming a significant 
cause of health care associated.22-26 Several epidemiological criteria have been 
used to classify MRSA infections, although the classification scheme has not been 
standardized.27-29 The general criteria for classification include the following: the 
time of isolation, host risk factor profiles, antimicrobial susceptibility patterns, and 
molecular characteristics of the isolate (Table 1.2). 
Table 1.224,29,30 Classification of MRSA 
Classification Definition 
HA-MRSA MRSA infection in a patient with one of the following risk factors: 
presence of an invasive device at time of infection, history of HA-
MRSA, history of surgery, hospitalization, dialysis, or residence 
in a long-term care facility in the 12 months preceding culture. 
CA-MRSA MRSA infection with onset in the community in a patient who is 
without risk factors for HA-MRSA.  
Hospital-onset  The CDC ABC Surveillance System defines invasive hospital-
onset HA-MRSA cases with positive culture result from a 
normally sterile site obtained >48 hours after hospital admission. 
Community-onset The CDC ABC Surveillance System defines invasive community-
onset HA-MRSA as cases with onset in the community and at 
least one of the HA-MRSA risk factors. 
HA-MRSA=health care associated methicillin resistant S. aureus; CA-
MRSA=community-associated methicillin resistant S. aureus; CDC=the US 
Centers for Disease Control and Prevention; ABC Surveillance System=the Active 
Bacterial Core Surveillance Program.  
 
MRSA strains have been characterized by certain bacteriologic features 
including antimicrobial susceptibility patterns and genotype. Molecular subtyping 
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has been important in tracking the spread of infections and transmission of strains, 
determining source of infections, monitoring trends, and confirming the 
effectiveness of established prevention efforts. Numerous approaches have been 
used for subtyping of MRSA. Common approaches include the subtyping of the 
staphylococcal cassette chromosome element (SCCmec), pulsed-field gel 
electrophoresis (PFGE), carriage of Panton Valentine Leukocidin (PVL) genes, 
and multilocus sequence typing (MLST). 
PFGE is commonly used for molecular typing of S. aureus isolates in the 
US.31-34 This method relies on separation of SmaI-digested S. aureus genomic 
DNA fragments according to size in an agarose gel by pulsed-field electrophoresis. 
Related strains are clustered according to an 80% similarity coefficient. The CDC 
developed a national PFGE database for S. aureus that uses the “USA” 
designation. PFGE types USA100, USA200, USA500, USA600, and USA800 are 
predominant health care–associated strains, whereas USA300 is the predominant 
community-associated S. aureus strain. The USA300 designation has been used 
to characterize ST8 and PVL-positive CA- MRSA.21 
MRSA strains can be characterized by the mobile genetic element (MGE), 
SCCmec, which harbors the mecA gene encoding for methicillin resistance.35 To 
date, there have been 11 SCCmec elements that have been identified. HA-MRSA 
typically carry a large SCCmec element belonging to type I, II, or III. SCCmec II 
(53 kb) and SCCmec III (67 kb) are large and possess other mobile genetic 
elements, such as integrated plasmids (e.g., pUB110, pI258, and pT181) and 
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transposons (e.g., Tn554).36 In contrast, CA-MRSA strains carry smaller elements, 
SCCmec IV (21–24 kb) and V (27 kb), are generally susceptible to non-beta-lactam 
antibiotics, and frequently carry PVL genes.2,37 
MLST is a genotyping method based on sequences. This method analyzes 
single nucleotide variations (e.g. alleles) within 7 housekeeping genes in S. 
aureus. Isolates that have identical sequences are considered a clone and are 
assigned a unique sequence type (ST). S. aureus isolates with similar identity at 5 
of the 7 housekeeping genes based on MLST are grouped into major lineages, 
named clonal complexes (CC).37,38 CCs can be constructed based on ST’s through 
a web-implemented algorithm called BURST (Based Upon Related Sequence 
Types), allowing the expansion or emergence of clones to be put in the context of 
their genetic background. MRSA strains have been generally grouped into a 
subset of CCs, including CC1, CC5, CC8, CC22, CC30, and CC45.39,40,41The first 
MRSA clinical isolates (COL as an example) were ST250, belonging to the CC8 
lineage. The predominant CA-MRSA strains have been classified as ST8 
belonging to the CC8 lineage.39 MLST has been useful to identify outbreaks and 
expansions; however, different algorithms and more genomic information are 
required to determine more deep-rooted relationships within the population. 
In summary, the molecular distinction between HA-MRSA and CA-MRSA is 
increasingly blurred. It has become more difficult to determine whether MRSA 
strains associated with outbreaks are related to health care workers, other 
patients, the hospital environment, or the community.21,22,42-45 Rapid WGS has 
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proven to be much more discerning; but, has yet to be widely available. In general, 
HA-MRSA strains tend to have a multidrug-resistant profile, carry SCCmec type II 
or III, and have a USA100 or USA200 PFGE pattern. Comparatively, CA-MRSA 
strains are typically susceptible to non β-lactam antibiotics, carry SCCmec type IV 
or V, and typically have a USA300 or USA400 PFGE pattern. Table 1.3 provides 
a summary. 
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Table 1.3 Major clonal complexes of S. aureus and select genome sequencing 
projects46 
 
Clonal 
Complex 
Multilocus 
Sequence Type 
Common Names 
and/or PFGE types 
Comment Whole genome 
Accession No 
CC1 ST1 USA400 and MW2 
 
First US CA-MRSA strain, 
SCCmecIV and PVL-positive, 
pediatric fatal septicemia, 
USA, 1998 
BA000033 
CC5 ST5 
 
ST5 
USA100 and New 
York/Japan clone, 
Mu50 
USA800 and 
pediatric 
clone/EMRSA 
Most common US health 
care–associated MRSA, 
SCCmecII 
Among earliest recognized 
SCCmecIV-bearing strains.  
BA000017 
 
 
CC8 ST250 
 
ST247/ST239 
ST239 
ST254 
ST8 
 
 
ST8 
ST8 
COL 
 
Iberian Clone 
EMRSA-5 
Brazilian, EMRSA-1 
EMRSA-10 
USA300, FPR3757, 
LAC 
 
 
NCTC8325 
Newman 
First (archaic) MRSA clinical 
isolate, SCCmecI, UK 1961 
Descendant of COL 
SCCmecIII 
SCCmecIV 
Predominant US CA-MRSA 
strain, SCCmecIV and PVL-
positive, ACME-positive, 
Abscess, USA 2000 
MSSA, UK, 1949 
MSSA, clumping factor 
overproducer UK, 1941 
CP000046 
 
 
 
 
CP000255 
 
 
CP000253 
AP009351 
CC22 ST22 EMRSA-15 International clone, prominent 
in Europe and Australia 
 
CC30 ST30 
 
ST30 
 
ST36 
USA1100 
 
SWP 
 
USA200 and 
EMRSA16 
Uncommon US CA-MRSA, 
SCCmecIV and PVL-positive 
Southwest Pacific clone, CA-
MRSA, SCCmecIV and PVL-
positive 
Single most abundant cause 
of MRSA infections in UK; 
second most common cause 
of MRSA infections in US 
hospitals in 2003 
 
 
 
 
BX571856 
CC45 ST45 USA600 SCCmecII  
CC=clonal complex; PFGE=pulsed-field gel electrophoresis; ST=sequence type. 
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Burden of illness due to S. aureus associated SSTIs 
S. aureus is a leading cause of infections globally, and is responsible for 
more annual deaths in the U.S. than HIV. In 2011, MRSA was responsible for 
80,461 cases of invasive disease and 11,285 related deaths in the U.S.30  
While S. aureus has traditionally been a leading cause of SSTIs, its 
prominence has dramatically increased in parallel with the emergence of CA-
MRSA. A study based in Texas found a 7-fold increase in the incidence of CA-
MRSA infections from 1997 to 2000 compared to 1990 to 1996.47 By the mid-
2000’s, CA-MRSA accounted for more than 50% of skin abscesses in U.S. 
emergency departments and hospitals.48 In the primary care setting, CA-MRSA 
accounts for 38% to 61% of culture-positive SSTIs.49-51 In 1997 to 2005, the annual 
incidence of outpatient visits for SSTIs increased 50%, from 32 per 1000 to 48 per 
1000 visits. S. aureus associated SSTI hospitalizations have also increased.52 
Klein et al. reported that the estimated number of MRSA-related hospitalizations 
across all infection types doubled from 127,036 in 1999 to 278,203 in 2005.53 In a 
study using the Nationwide Inpatient Sample, Suaya et al. reported that S. aureus 
SSTI associated hospitalizations increased 123% between 2001 and 2009, with 
the highest increase in incidence seen among children 0-17 years of age. The 
investigators noted that the observed increase in S. aureus hospitalizations 
occurred simultaneously with the emergence of the CA-MRSA USA300 clone.54 
Similarly, Frei et al. found that pediatric hospitalizations for both S. aureus 
associated SSTIs increased from 1996 to 2006.55 Recently, Lee et al. reported that 
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MRSA SSTI associated hospitalizations in the U.S. has increased more than 30-
fold among pediatrics, and 8-fold among adults from 2001 to 2010 (Figure 1.2) 
(unpublished data).  
 
 
Figure 1.2 Adult and pediatric hospitalizations for MRSA associated SSTIs in the 
United States from 2000 to 2010 
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Cost of illness due to S. aureus SSTIs 
The costs associated with the management of S. aureus infections can be 
substantial. Costs vary by population, setting, cost perspective, and treatment 
approach. In U.S. hospitals, the treatment of S. aureus infections cost more than 
$14.5 billion annually.54 In 1997, Marton et al. reported that the mean overall cost 
of an SSTI episode among inpatients and outpatients was $8,865.56 In 2006, 
Menzin et al. estimated that the mean associated hospitalization cost for S. aureus 
SSTIs was $6,800.57 In a study among hospitalized patients with gram-positive 
bacteria associated SSTIs, the median charge was $19,894.58 Recently, Lee et al. 
estimated the total direct health care costs of SSTIs to be $14.9 billion in 2012, 
representing a 3-fold increase from $4.8 billion in 2000. This was largely driven by 
an 8-fold increase in ambulatory expenditures for SSTIs (Figure 1.3). The mean 
expenditures for ambulatory visits increased 5-fold from $253 [standard error (SE) 
+ $33] in 2001 to $1,336 (SE + $240) in 2010 (unpublished data). 
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Figure 1.3 Proportion of direct expenditures for SSTIs by health care service in 
the United States, 2000 and 2012 
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Risk factors for S. aureus SSTIs 
CA-MRSA causes infections in many different hosts, ranging from young 
healthy individuals without traditional risk factors to those with extensive underlying 
diseases and health care exposures.59 Prior studies have identified several risk 
factors for CA-MRSA SSTIs. Table 1.4 highlights common risk factors for CA-
MRSA SSTIs. SSTIs due to MRSA predominantly affect children, adolescents, and 
middle-aged adults; the median age for adults ranges from 20 to 47 years. CA-
MRSA SSTIs have been found to be more frequently identified among males, 
African Americans, and those with a history of a prior skin infection.13,19,23,47,51,60-73 
Crowding and sharing of personal items are also important factors.60,66,68 The 
transmission of CA-MRSA has been demonstrated through direct contact among 
football players, wrestlers, and military trainees.33,60,62 Household spread of CA-
MRSA has proven to be an important reservoir for transmission.74,75 In 
approximately 15% of cases, MRSA-infected patients reported having close 
contact with a person who had a similar skin infection. While prior antimicrobial 
exposures have been inconsistently associated with MRSA, the risk appears to be 
highest for fluoroquinolone and macrolide exposures. Furthermore, other host risk 
factors such as obesity and body size have been reported.63,64,69,76  
Recently, Lee et al. performed a case-case-control study within 14 primary 
care clinics in South Texas from 2007 to 2015. Overall, 325 patients [S. aureus 
SSTI cases (Case Group 1)=175; MRSA SSTI cases (Case Group 2)=115; MSSA 
SSTI cases (Case Group 3)=60; uninfected control group (Control)=150 were 
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evaluated]. Each Case Group was compared to the control group, and then 
qualitatively contrasted to identify unique risk factors associated with S. aureus, 
MRSA, and MSSA SSTIs. Overall, prior SSTIs, male gender, and non-healthcare 
occupation were predictors for S. aureus SSTIs. The only unique risk factor for CA-
MRSA SSTIs was a high body weight (publication in review). 
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Table 1.4 Summary of clinical studies identifying risk factors for CA-MRSA SSTIs 
Study Geographic 
area 
Setting Population Comparator 
Group 
Risk factors 
Moran48 
(2007) 
n=422 
11 U.S. cities ED SSTIs Other 
pathogens 
Antibiotic use in the past month, non-Hispanic 
African American, reported spider bite, history of 
MRSA infection, close contact with persons with 
skin infection 
King77  
(2006) 
n=389 
Atlanta, GA Outpatient, 
Hospital 
S. aureus 
SSTIs 
CA-MSSA Female gender, African-American, hospitalization 
within the past year 
Hota67  
(2007) 
n=1,222 
Chicago, IL ED, 
Outpatient, 
Hospital 
S. aureus  CA-MSSA Younger age, HIV infection and incarceration 
within the past year, African American 
Lee71  
(2005) 
n=111 
Los Angeles, 
CA 
Outpatient MSM, HIV Control Sex partner with skin infection, methamphetamine 
use, routine hand-on contact with customers at 
work, frequent fingernail biting, routine use of a 
public hot tub or sauna 
Al-Rawahi78  
(2008) 
n=190 
Vancouver, 
Canada 
ED MRSA HA-MRSA Presence of abscesses or cellulitis, injection drug 
use 
Campbell62  
(2004) 
n=202 
San Diego, 
CA 
Outpatient Military 
personnel 
Control Close contact with persons with skin infection, 
having family or friends working in health care 
setting 
Kazakova79  
(2005) 
n=53 
St. Louis, 
MO 
Outbreak Football 
Players 
Non-SSTI 
controls 
Being the lineman or linebacker position, high BMI 
Coronado80  
(2007) 
n=175 
New York, 
NY 
Outbreak Religious 
community 
Non-SSTI 
controls 
Antibiotic use within 12 months, sauna use 
Khawcharoenporn69 
(2010) 
 n=137 
Honolulu, HI Outpatient SSTI SSTI due to 
other bacteria 
Presence of abscesses, obesity (BMI > 30) 
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Table 1.4 (Cont.) Summary of clinical studies identifying risk factors for CA-MRSA SSTIs 
Study Geographic 
area 
Setting Population Comparator 
Group 
Risk factors 
Casey63 
(2013) 
n=78,216 
U.S. Hospital, 
Outpatient 
SSTIs Controls, HA-
MRSA 
Age, season, community socioeconomic deprivation, 
obesity, smoking, prior SSTI, and antibiotic administration 
Landrum81 
(2012) 
 
U.S. Hospital SSTIs HA S. aureus Age 18-24 years, men, active duty, living in the Southern 
U.S. 
Cadena61 
(2015) 
n=112 
San Antonio, 
TX 
Hospital, 
Outpatient 
MRSA nasal 
carriers at 
discharge 
Controls Prior hospital admission, prior MRSA infection, 
myocardial infarction 
Lee 
(2015) 
n=325 
South Texas Outpatient S. aureus 
SSTIs 
CA-MSSA, 
Controls 
Prior SSTI and body weight > 110 kg 
CA-MRSA=community-associated methicillin-resistant Staphylococcus aureus; CA-MSSA=community-associated methicillin 
susceptible Staphylococcus aureus; ED=emergency department; HA-MRSA=healthcare-associated methicillin resistant 
Staphylococcus aureus; HIV=human immunodeficiency virus; MSM=men who have sex with men; SSTI=skin and soft tissue 
infection 
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Treatment of S. aureus SSTIs 
The Infectious Diseases Society of America (IDSA) developed the ‘Practice 
Guidelines for the Management of SSTIs: 2014 Update by the IDSA’.82 A summary 
of the management recommendations are shown in Figure 1.4. The IDSA asserts 
that incision, evacuation of pus and debris, and probing the cavity to break up 
loculations is the primary treatment of purulent staphylococcal skin abscesses. 
Patients with abscesses caused by S. aureus are frequently cured by incision and 
drainage (I&D) alone.83 This contention has been supported by several 
observational studies that described patients who received inappropriate MRSA 
antimicrobials or no antimicrobials were cured, nevertheless.14,50,84,85 In a 
randomized clinical trial, patients with uncomplicated SSTIs were randomized after 
I&D to receive either cephalexin or placebo. Despite 88% of isolates being MRSA, 
cure rates remained high and did not significantly differ between the two groups 
(84.1% vs. 90.5%).85 
Although I&D alone may be sufficient for treatment in many SSTI cases, 
there are likely to be subgroups in which antibiotic therapy is needed. The 2014 
IDSA guideline recommends adjunctive antibiotics for purulent SSTIs in patients 
who have failed I&D plus oral antibiotics, those with systemic signs of infection 
such as temperature >38°C, tachycardia (heart rate >90 beats per minute), 
tachypnea (respiratory rate >24 breaths per minute) or abnormal white blood cell 
count (<12 000 or <400 cells/µL), or patients who are immunocompromised.82 
Furthermore, several studies have shown that appropriate MRSA therapy in 
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addition to I&D has been associated with higher cure rates.69,86-91 In a retrospective 
study of hospitalized patients with CA-MRSA SSTIs, treatment failure occurred 
less frequently when MRSA-appropriate antibiotics were administered within 48 
hours. compared to when MRSA-inappropriate therapy was used (5% vs. 13%; 
p=0.001).92 A recent study of treatment outcomes of patients with MRSA SSTIs 
found I&D with adjunctive antibiotics was the only predictor of treatment success. 
Patients treated with appropriate antibiotics demonstrated significantly higher cure 
rates compared to those who received inappropriate therapy (91.3% vs. 75.4%; 
p<0.05).90  
The efficacy of various antibiotics in the treatment of CA-MRSA SSTIs in 
the clinic setting is not well defined. However, clindamycin and trimethoprim-
sulfamethoxazole (TMP-SMX) are recommended due to their relatively low cost 
and good activity against both CA-MRSA and MSSA strains. A recent randomized 
clinical trial compared clindamycin and TMP-SMX for the treatment of 
uncomplicated skin infections and found no significant differences between the two 
groups with respect to efficacy, and safety outcomes.84 Further comparative 
effectiveness studies are required to identify which antibiotic, if any, is optimal in 
the treatment of staphylococcal skin infections.  
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Figure 1.4 Overview of the management of SSTIs82 
 
 
 
 
SSTI=skin and soft tissue infection; Rx=antimicrobial therapy; I&D=incision and 
drainage; C&S=culture and susceptibility testing; “severe”=patients who have failed 
incision and drainage plus oral antibiotics or those with systemic signs of infection such 
as temperature >38°C, tachycardia (heart rate >90 beats per minute), tachypnea 
(respiratory rate >24 breaths per minute) or abnormal white blood cell count (<12 000 or 
<400 cells/µL), or immunocompromised patients; “moderate”=patients with systemic 
signs of infection; “mild”=typical cellulitis/erysipelas or purulent SSTI with no systemic 
signs of infection. 
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Antimicrobial Resistance in S. aureus 
Resistance to antibiotics is common among infections caused by S. 
aureus.2,16,93,94 The most clinically important has been the development of 
methicillin resistance. Methicillin resistance also infers resistance to most all of the 
β-lactam class, which are the most effective against S. aureus. Methicillin 
resistance is usually due to the horizontal gene transfer of a mobile genetic 
element, SCCmec, carrying the mecA gene into the S. aureus chromosome. The 
mecA gene codes for a penicillin binding protein (PBP2a), which results in 
decreased affinity to methicillin and all β-lactam antibiotics.95 As a result, methicillin 
(and other β-lactam antimicrobials) cannot efficiently bind to the bacterial cell, 
which results in reduced capacity to inhibit cell-wall synthesis.  
Non β-lactam antibiotics are commonly used for the treatment of S. aureus 
in the outpatient setting. Reported susceptibility profiles of USA300 strains are 
summarized in Table 1.5. USA300 MRSA strains are usually susceptible to 
trimethoprim-sulfamethoxazole, doxycycline, rifampin, and gentamicin; whereas, 
the majority is resistant to erythromycin (50-95%).96 Overall, USA300 isolates are 
typically susceptible to most antimicrobial classes; however, reports of 
antimicrobial resistance have been increasingly reported.16,33,97-99 
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Table 1.5 Antimicrobial susceptibility profiles of CA-MRSA 
 
Study Clone  
 
AG CLIN ERY FA FQ MUP RIF TET TMP/SMX VAN 
McDougal 
et al.118  
USA300  99 93 n/a n/a n/a 97 n/a 91 99 n/a 
Mendes 
et al.98  
USA300 n/a 93.5 1.8 m/a 57.4 n/a n/a 91.3 99.6 100 
David MZ 
et al.27  
 
USA400 95.8 42.5 40 n/a 93.3 n/a 97.5 n/a 100 100 
Huang et 
al.42  
 
USA300 100 96 7 n/a 53 n/a 100 80 100 100 
Luna VA 
et al.119  
 
USA300 n/a 96 6 n/a n/a n/a n/a n/a n/a n/a 
CA-MRSA=community-associated methicillin resistant S. aureus; 
AG=aminoglycoside; CLIN=clindamycin; ERY=erythromycin; FA=fusidic acid; 
FQ=fluoroquinolones; MUP=mupirocin; RIF=rifampin; TET=tetracycline; 
TMP/SMX=trimethoprim/sulfamethoxazole; VAN=vancomycin 
 
Since 2001, USA300 isolates have become increasingly resistant to 
fluoroquinolones. In 2006, approximately 54% of the Active Bacterial Core 
surveillance isolates were resistant to levofloxacin.100 Previous studies have 
described numerous fluoroquinolone resistance mechanisms. These include 
chromosomal mutations in the gyrA and grlA genes, and the overexpression of a 
membrane-associated multidrug efflux pump, norA.101  
Resistance mechanisms for most other antimicrobials are often plasmid-
mediated and associated with transposons or insertion sequences.102-104 Among 
isolates with a susceptibility pattern that is resistant to penicillin, oxacillin, and 
erythromycin, two plasmids have been described: 1) a small (3.1 kb) cryptic 
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plasmid, and 2) a mosaic plasmid (27 kb) that harbors several antimicrobial 
resistance determinants, including erythromycin resistance (msrA) and penicillin 
(blaZ).33,105,106 A plasmid (4.4 kb) with the tetK gene has been reported among 
USA300 strains that are tetracycline resistant but susceptible to doxycycline and 
minocycline.33,102,107,108 
Clindamycin resistance among S. aureus in the U.S. has been reported to 
range from 2 to 7%.77 Resistance to clindamycin can be constitutive or inducible 
(i.e., inducible macrolide-lincosamide-streptogramin [MLSB] resistance). Due to 
reports of clindamycin treatment failures, the CDC recommends that isolates that 
test resistant to erythromycin and susceptible to clindamycin be further tested for 
inducible clindamycin resistance using the D-test.16,98,99,109,110 Isolates with 
clindamycin resistance have been reported to carry a small plasmid (2.6 kb) 
harboring the ermC gene.33  
With increasing pressure to prevent MRSA infections, there has been an 
increased use of mupirocin as a decolonization strategy. Prior studies have shown 
that the widespread use of mupirocin can lead to an increase in mupirocin 
resistance.111,112 High-level mupirocin resistance in S. aureus is mediated by a 
plasmid-encoded mupA gene. The mupA gene is found on conjugative plasmids 
that carry multiple resistance determinants for other classes of antimicrobial 
agents. High-level resistance has been associated with decolonization failure, and 
increased resistance rates have been associated with increased mupirocin use. 
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Low-level mupirocin resistance is mediated via a mutation in the native ileS 
gene.111,113,114  
Recent studies have described the increasing incidence of multidrug 
resistance among community-associated S. aureus strains.16,98 Multidrug 
resistance was first described in the first complete draft genome of an USA300 
CA-MRSA isolate.102 This strain had accumulated resistance to β-lactams, 
fluoroquinolones, tetracycline, macrolide, clindamycin, and mupirocin. It was 
discovered that the resistance determinants for 3 of these agents (macrolide, 
clindamycin, and mupirocin) were located on a large conjugative plasmid, pUSA03, 
carrying ermC and mupA. The pUSA03 plasmid is related to an older plasmid 
family that contains multiple copies of the insertion element IS257 which serve as 
integration sites for mobile elements that can carry various resistance 
determinants. These determinants include the aa6’-aph2”¸ which confers 
resistance to aminoglycosides; dfrA which confers high-level resistance to 
trimethoprim; mupA which confers high-level mupirocin resistance; and vanA 
which confers vancomycin resistance.102,104  
Since its discovery, S. aureus has acquired resistance to virtually all 
antibiotics. More recently, reports of vancomycin resistant S. aureus and strains 
resistant to newer antibiotics such as linezolid, daptomycin, and ceftaroline have 
been reported.115-117 Multidrug-resistant MRSA strains remain an alarming 
situation.  
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Virulence factors in S. aureus 
S. aureus is a major human pathogen responsible for a wide array of 
infections. Staphylococcal infections can cause a broad range of clinical 
manifestations and can usually be subdivided into three main groups: superficial 
lesions (e.g., SSTIs), invasive infections (e.g., pneumonia, endocarditis, and 
osteomyelitis), and toxinoses (e.g. food poisoning, toxic shock syndrome). The 
ability of S. aureus to cause infections is dependent upon its extensive 
armamentarium of virulence factors. Host invasion by S. aureus and the 
establishment of infection involve several essential steps: 1) binding to the cell 
surface, 2) escape from the host immune system, and 3) dissemination and tissue 
invasion. These virulence factors can be broadly grouped according to three main 
roles during the infection process: (1) adhesins, which facilitate adherence to host 
tissues, (2) toxins, which cause tissue damage to the host; and (3) evasins, which 
interfere with host immune function (Table 1.6).9,94,120,121  
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Table 1.6 S. aureus virulence factors involved with infection 
Type of virulence 
factor 
Factors Genes 
Adhesins 
(MSCRAMM) 
 
Clumping factors, fibronectin- finbrinogen- 
binding proteins, collagen, and bone 
sialoprotein-binding proteins 
clfA, clfB, fnbA, 
fnbB, can, sdr, bbp, 
eap, isdA, emp, ebh 
Toxins Leukocidins (PVL, β toxin, gamma toxin, 
delta toxin, PSMα), capsular polysaccharides, 
protein A, phenol-soluble modulins, 
enterotoxins, toxic shock syndrome toxin-1, 
exfoliative toxins A and B, α-toxin 
Luk-S-PV, lukF-PV, 
hlg, cap5 and cap8 
gene clusters, spa, 
chp, eap, psm-α 
gene cluster 
Evasins Proteases, lipases, nucleases, hyaluronate 
lyase, phospholipase C, metalloproteases, 
catalase, superoxide dismutase 
V8, hysA, hla, plc, 
sepA, dlt, mprF 
MSCRAMM=microbial, surface components recognizing adhesive matrix molecules; 
PVL=panton valentine leukocidin; PSM=phenol soluble modulin 
 
Staphylococcal virulence molecules include those that inhibit neutrophil 
recruitment, promote direct lysis of neutrophils, and those that are involved in the 
formation of the fibrin capsule surrounding the abscess.  
S. aureus demonstrates an abundance of mechanisms to evade killing by 
phagocytes.122 S. aureus may hide from recognition by producing protective coats, 
such as capsular polysaccharide or biofilm produced by polysaccharide 
intercellular adhesion (PIA).122-125 It can also secrete specific molecules to block 
phagocyte receptor function. These bacteria have also been shown to use 
mechanisms to decrease the efficiency of antimicrobial activity within the 
phagosome, that can account for postphagocytic survival. S. aureus has the 
capacity to produce a molecule called CHIPS (chemotaxis inhibitory protein of S. 
aureus) that blocks receptor-mediated recognition of formylated peptides.122,126 
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Furthermore, other molecules secreted by S. aureus can block the host 
complement system, which results in reduced phagotysois after opsonization.   
After phagocytosis, S. aureus produces a diverse array of immune evasion 
molecules. These include catalase and superoxide dismutase to eliminate reactive 
oxygen species. Non-specific proteases are secreted to digest any protein-based 
antimicrobial effector. In addition, S. aureus can react in the presence of 
antimicrobial peptides (AMPs) by an up-regulation mechanism to interfere with the 
cationic activity of AMP.122,127  
S. aureus produces several virulence factors that contribute to the formation 
of abscesses and host immune evasion. The roles of each of these virulence 
factors are discussed. 
Panton valentine leukocidin (PVL) is an exotoxin that is comprised of two 
subunits, LukS-PV and LukF-PV, encoded by ΦSa2.128 These subunits bind to 
specific membrane receptors to form pores in the membrane of host leukocytes, 
and at high concentrations, causes lysis of white blood cells. However, studies 
have yielded conflicting results of its role in disease severity. In the early 1990’s, 
PVL was epidemiologically linked with S. aureus skin infections and with the 
enhanced virulence of CA-MRSA infections.129-132 In a meta-analysis, the 
presence of PVL was associated with abscesses and furuncles (odds ratio 10.5; 
95% CI 7.4-14.9).133 However, the extent of PVL production was not associated 
with more severe disease. Evidence from animal models does not conclusively link 
PVL and the pathogenesis of S. aureus skin infections. In mice, PVL-negative 
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USA300 S. aureus strains demonstrated no difference to PVL-positive strains in a 
skin infection model.134,135 It was later discovered that mouse neutrophils are 
resistant to the toxic effects of PVL compared to humans, thus does not serve as 
an optimal model.136 Comparatively, rabbit models demonstrated the potential 
toxic effects of PVL. A recent study compared isogenic PVL-knockout mutants, 
and found that PVL-positive MRSA strains exert toxic effects on keritonocytes that 
facilitate local spread and inflammation.129 However, in a another rabbit model 
study, PVL-positive and PVL-negative strains produced comparable severity in 
disease.137 Currently, the contribution of PVL to S. aureus pathogenesis remains 
inconclusive. 
Phenol soluble modulin-like peptides (PSMs) are a group of small proteins 
in S. aureus that has the capacity to lyse host cells including neutrophils and 
erythrocytes.9,10,120,138 High expression of PSMs has been associated with 
enhanced virulence of MRSA. In a mouse abscess model, PSM deletion resulted 
in significantly less severe skin lesions. The level of PSM production was found to 
be significantly higher in USA300 MRSA clones than other MRSA clones. In a 
rabbit skin infection model, α-hemolysin, PSM, and agr, were associated as main 
contributors to the pathogenicity of MRSA isolates.139  
Another toxin, α-toxin (α-hemolysin, Hla) and its role in S. aureus virulence 
has been well studied. α-hemolysin has the capacity to form pores in various 
human cells, including red blood cells, epithelial cells, fibroblasts, and 
monocytes.138,140,141 In a rabbit skin infection model, the expression level of α-
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hemolysin was correlated with virulence. High levels of α-hemolysin have also 
been associated with severe skin infections due to an ST93 MRSA clone.142 Early 
vaccination studies demonstrated that mice that were vaccinated against α-
hemolysin were associated with less severe skin disease.143  
More recently, the pathogencity of USA300 MRSA strains has been 
associated with the arginine catabolic mobile element (ACME).144 ACME is 
adjacent to the SCCmecIV and contains two potential virulence factors including a 
cluster of arc genes that encode an arginine deiminase pathway and Opp-3, which 
encodes an oligopeptide permease operon.102,145,146 Specifically, the speG gene 
within the ACME locus was found to be associated with increased resistance to 
polyamines that are produced on the skin, which are toxic to other S. aureus 
strains. In addition, a rabbit bacteremia model showed that the deletion of ACME 
(but not SCCmec) was shown to decrease fitness of USA300 MRSA strains.144 
This supported a key advantage for ACME containing strains for skin colonization 
and infection. 
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Pathogenesis of S. aureus SSTIs 
S. aureus is responsible for 85 to 95% of all skin infections. The propensity 
for S. aureus to infect the skin involves a balance between the host’s cutaneous 
immune defense mechanisms and virulence factors of the pathogen.  
The skin is the first line of defense against invading pathogens. The skin 
provides a physical barrier to prevent bacteria from entering into deeper layers of 
tissues and/or invasion to other internal organ systems. Therefore, breach of the 
skin allows entry of pathogenic organisms into the tissue and initiates an immune 
response to the site of infection. 
Approximately 65% of S. aureus SSTIs present as pyogenic abscesses that 
form in the dermis, epidermis, or subcutaneous tissue and are frequently present 
with surrounding cellulitis.83 The overall structure of S. aureus abscesses begins 
as an acute localized host inflammatory response.147 The center of the abscess 
comprises of an exudate composed of viable and necrotic polymorphonucleocytes 
(PMNs), tissue debris, fibrin, and bacteria. The abscess maturation is then 
accompanied by the formation of a fibrous capsule at the periphery due to 
fibroblastic proliferation and tissue repair. Keratinocytes on the skin possess 
receptors that detect patterns in invading microbes which signal the pro-
inflammatory response.148,149  
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Neutrophil recruitment is arguably the most important cellular defense 
against S. aureus. Neutrophils play an important role in the formation and 
resolution of S. aureus abscesses. Findings in mice and humans have suggested 
important roles for IL-1 and IL-17 in host defense against cutaneous S. aureus 
infections.151-153 Neutrophils are rapidly recruited to the infection site to initiate the 
phagocytosis process to remove invading organisms. Receptors on the surface of 
host neutrophils and other phagocytes play an essential role in recognizing 
bacteria by promoting chemotaxis and activation. Bacteria have a multitude of 
surface molecules that interact with receptors on the surface of neutrophils. These 
pattern recognition receptors (e.g. Toll-like receptors and CD14) activate signal 
transduction pathways that lead to bactericidal activity.148,154-156 This occurs 
primarily by opsonization of bacteria with antibody and complement. Antibodies 
bind to the epitopes on the surface of bacteria. These antibodies that are bound to 
the bacterial surface are then recognized by neutrophil receptors specific for the 
Fc region. The ingested bacteria are engulfed within membrane-bound vacuoles 
(phagosomes). Following polymorphonucleocytes (PMN) phagocytosis, signal 
transduction of various bactericidal mechanisms is initiated, including the 
production of superoxide radicals and other reactive oxygen species (ROS), 
production of antimicrobial peptides (AMP) that have activity against S. aureus, 
proteins, and degradative enzymes.122,127,150,157,158  
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S. aureus colonization 
S. aureus is normally a commensal and colonizer of the skin and mucosa 
of humans and several animal species.94,159,160. The primary carriage site for S. 
aureus in humans is the anterior nares (foremost parts of the nose, covered by 
fully keratinized squamous epithelium containing hair follicles).161,162 But, the skin, 
throat, gastrointestinal tract, groin, anus, and the urogenital tract in women have 
all been identified as niches. Longitudinal studies have shown that 12-30% of 
individuals are persistent S. aureus carriers and approximately 30% are 
intermittent carriers of S. aureus. Overall MRSA carriage rates in the community 
setting are still low (~1.5%), but seem to be rising rapidly in certain regions.163,164 
The mechanisms leading to S. aureus nasal carriage are multi-factorial.  
Bacterial factors (e.g. staphylococcal toxins and adhesion molecules), 
environmental factors (e.g. hospitalization and prisons), as well as host 
susceptibility factors (e.g. immune suppression, loss of normal skin barrier, 
malignancies) all play a role in successful S. aureus coloniziation.60,165,166 Nouwen 
et al. conducted a study where subjects (non-carriers and persistent carriers) were 
inoculated with a mixture of S. aureus strains. This study demonstrated that non-
carriers quickly eliminated the inoculated S. aureus strains, whereas most 
persistent carriers selected their original resident S. aureus strain from the 
inoculation mixture.160 S. aureus carriage rates have been reported to vary 
depending on age, race, ethnicity, geographic location, and body niche. Carriage 
has shown to be higher among patients with diabetes mellitus, end-stage renal 
 33 
disease undergoing hemodialysis, end stage liver disease, HIV, skin disease, 
obesity, and history of a cerebrovascular accident. Environmental factors such as 
hospitalization are important risk factors for nasal carriage state. In addition, 
community households have been determined to be a critical reservoir for S. 
aureus.74,75 Peacock et al. found concordant carrier states between mothers and 
their children. Bogaert et al. also found that most mothers carry the same strain as 
their children, further indicating that carriage strains are transmitted to close 
contacts.165  
 Nasal colonization of S. aureus has been described to occur in several 
steps. First, the nose has to come in contact with S. aureus. Second, S. aureus 
needs to adhere to certain receptors in the nasal niche. Third, S. aureus needs to 
overcome the host defenses. Finally, S. aureus must be able to propagate in the 
nose.  
Colonization is an important risk factor for invasive disease and source of 
spread of S. aureus among individuals.163,167 Several older studies have 
investigated the relationship between S. aureus nasal carriage and skin infections, 
including furunculosis, impetigo, sycosis barbae, stye, osteomyelitis, infective 
endocarditis, and respiratory tract infections (cystic fibrosis).168-171 On average, 
80% (range 42–100%) of those with skin lesions were S. aureus nasal carriers, 
and 65% (range 29–88%) had the same phage type in the nose and lesion. In a 
prospective study, Ellis et al. found a higher risk (relative risk 3.1, 95% CI 1.5-6.5) 
 34 
for nasal carriers of MRSA to acquire a community-associated MRSA infection 
(i.e., cellulitis, abscess).172  
There is controversy as to whether all S. aureus strains have equal disease 
invoking potential or whether invasive disease is associated with particularly 
virulent genotypes. While it has been well established that nasal colonization is a 
predisposing factor for noscomial infections, the potential role for opportunistic 
infections in other sites and syndromes are unknown. Few studies have 
investigated the potential of commensal S. aureus strains and their capacity to 
cause invasive disease.173-176 In a study of 219 bacteremic patients, S. aureus  
isolated from blood could not be distinguished by PFGE from concomitantly carried 
nasal bacteria in the majority of cases.177 Conversely, in a major study, Feil et al. 
found no significant differences in the distribution of genotypes based on MLST 
between strains isolated from carriers and those from patients with invasive 
disease.39 This study suggested that there was no evidence for the existence of 
hyper-virulent S. aureus clones. A subsequent microarray analysis comparing 
community associated invasive isolates and 100 nasal carriage isolates did not 
reveal differences in lineage or gene content associated with pathogenic 
potential.178 Sabat et al. found that there was also no significant difference in the 
prevalence of genes encoding for adhesive proteins (SdrC, SdrD, and SdrE) 
between commensal (n=259) and invasive isolates (n=141) from different 
countries.179 By contrast, Melles et al. reported that subclusters of strains have 
different proportions of those that were isolated from invasive infections. This study 
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also revealed that all major clusters contained both invasive and non-invsaive 
isolates. The investigators concluded that given the right clinical condition, 
essentially any S. aureus genotype carried by humans can transform into an 
invasive pathogen, although certain clones may be more virulent than others.180 
Contemporary studies to better understand the ecology, pathogenesis, and 
epidemiology of S. aureus nasal carriage and its relation to skin infections are 
needed to develop and target preventive measures. 
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CHAPTER TWO 
Translational science of bacterial whole genome sequencing  
 
Application of bacterial whole genome sequencing (WGS) 
WGS is a process that yields all of the available DNA information from a 
genome. Over the last decade, significant advances have been made with next 
generation sequencing technology (NGS). NGS systems are powerful platforms 
that allow for massively parallel sequencing reactions and are capable of analyzing 
billions of sequencing reactions simultaneously. The first draft of the human 
genome sequence took ~13 years and over $3 billion.25,26 With the advent of NGS, 
the complete human genome sequence can now be assembled in less than 5 days 
at a cost of $2,000. NGS has the potential to revolutionize fields such as 
personalized medicine, genetic diseases, and clinical diagnostics. 
WGS of bacteria is poised to transform the practice of clinical microbiology 
and management of infectious diseases. The rapidly falling cost and turnaround 
time indicate that microbial WGS will become a viable technology in diagnostic and 
reference laboratories in the future. WGS has started to transform our 
understanding of the evolution of pathogens, identify the global spread of 
antimicrobial resistance, and represents the most significant advancement in 
diagnostic microbiology and surveillance since in vitro culture. In principle, WGS 
data contains all the information a clinician would need to direct treatment and 
provide public health surveillance in a single step. Over the last several years, 
 37 
many studies have demonstrated the value of WGS for species identification, 
antimicrobial susceptibility and virulence prediction, and outbreak detection.  
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WGS for controlling antimicrobial resistance 
WGS has been found to have numerous applications in controlling 
antimicrobial resistance ranging from the development of novel antibiotics, 
antimicrobial resistance surveillance, and antimicrobial susceptibility testing in the 
practice setting.181,182  
WGS has been instrumental in reconstructing the evolution of antimicrobial 
resistance and elucidating novel mechanisms of resistance. In a recent study, 
Long et al. used WGS to identify two novel amino acid altering mutations within 
the ceftaroline-binding pocket of PBP2a that were associated with ceftaroline 
resistance.117 Peleg et al. characterized the genetic evolution of daptomycin 
resistance in S. aureus. The investigators identified novel point mutations in genes 
coding for membrane phospholipids (cls2 and pgsA) that were associated with the 
development of daptomycin resistance.183 Furthermore, Alam et al. used WGS to 
identify genetic variants associated with vancomycin-intermediate S. aureus 
(VISA) strains. The study also developed a model to predict VISA based on the 
presence of these mutations in a set of candidate genes.184  
WGS has also been pivotal in validating and improving accuracy of current 
diagnostic assays by identifying novel resistance mechanisms. For instance, WGS 
led to the discovery of mecC (a homologue to mecA, a methicillin-resistance gene 
in S. aureus). This led to the redesign of clinical PCR (polymerase chain reaction) 
arrays to avoid false-negatives of MRSA detection.185 
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S. aureus infections are associated with significant morbidity, mortality, and 
health care costs. Time to appropriate diagnoses and treatment is a vital 
component of health outcomes. Prior studies have shown that every hour of 
inappropriate antibiotics substantially increases mortality among septic patients.186 
However, current culture and sensitivity practices take up to five days for results. 
The use of rapid susceptibility testing to guide appropriate treatment of S. aureus 
infections is sorely needed. Because WGS extracts the sum of all the bacterial 
genetic information, it can potentially determine a plethora of phenotypic 
characteristics, including antimicrobial resistance determinants. WGS can 
potentially identify the presence and absence of antimicrobial resistance genes 
and chromosomal mutations associated with reduced antimicrobial 
susceptibility.181,187  
Several studies have found concordance between the genotype derived by 
WGS and a phenotypically derived antibiogram (Table 2.1).188-192 Koser et al. 
compared antimicrobial susceptibilities of 13 antimicrobials in 14 clinical strains. 
The study found complete concordance between genotype-phenotype profiles for 
antimicrobial resistance.191 Eyre et al. evaluated isolates from a hospital outbreak 
affecting eight patients. All outbreak cases were mecA positive and harbored two 
plasmids that contained the blaZ and tetK genes, encoding for penicillin and 
tetracycline resistance, that aligned with the phenotype.189 Similarly, in a pilot study 
among 13 CA-MRSA isolates, Lee et al. found complete concordance of genotypic 
characteristics and its respective antimicrobial susceptibility phenotype.192 In the 
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largest study to date, Gordon et al. sought to develop a method for genotypic 
prediction of antimicrobial susceptibilities from whole genome sequences of 501 
S. aureus strains collected from two hospitals in England. This study compared the 
routine antimicrobial susceptibility testing results of 12 common antibiotics to WGS 
data to develop the panel of antimicrobial resistance determinants. This panel was 
subsequently used on a “validation set” of 491 unrelated S. aureus strains, which 
yielded an overall sensitivity and specificity of 0.97 (95% CI, 0.95-0.98) and 0.99 
(95% CI, 0.99-1), respectively. The very major discrepancy rate was 1.2% and a 
major discrepancy rate was 0.3%.190 These error rates were comparable with error 
rates of current phenotypic tests, and within acceptable limits set by the Food and 
Drug Administration (FDA) for new susceptibility testing. Finally, Bradley et al. 
implemented a rapid antibiotic resistance detection tool (“Mykrobe predictor”) on 
an independent set of 470 S. aureus strains. This method had comparable error 
rates when compared to standard antibiotic susceptibility methods, with a 
sensitivity and specificity of 99.1% and 99.6%, respectively.193  
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Table 2.1 Summary of studies evaluating WGS to detect antimicrobial resistance  
Study Genotype-Phenotype Concordance 
Koser et al. (n=14) 100% concordance 
Eyre et al. (n=8) 100% concordance 
Lee et al. (n=13) 100% concordance 
Gordon et al. (n=501 derivation; 
n=491 validation) 
Sensitivity=97%; specificity=99% 
VME=1.2%; ME=0.3% 
Bradley et al. (n=470) Sensitivity=99.1%; specificity=99.6% 
WGS=whole genome sequencing; VME=very major error; ME=major error 
 
Overall, several studies have documented the potential value of 
antimicrobial resistance profile predictions of S. aureus based on WGS data. 
However, the distribution and detection of antimicrobial resistance determinants 
among S. aureus in the outpatient setting is unknown. Because the majority of CA-
MRSA cases occur in the outpatient setting, studies evaluating the feasibility of 
using WGS data from community-associated S. aureus isolated from outpatient 
profiles are needed. Before WGS data can be used in the clinical setting for 
antimicrobial resistance prediction, multiple larger studies using diverse sets of 
unrelated S. aureus isolates are needed to validate the concordance of genotypic 
profiles relative to the phenotypically derived antibiogram. Furthermore, it is 
unclear whether current breakpoints (determined by in vitro MICs) or the presence 
of specific genetic mechanisms is more predictive of antimicrobial activity.  
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WGS to predict pathogenicity and virulence 
There is a growing body of evidence that suggests that the pathogenicity 
and virulence of bacteria can be predicted by microbial genotyping.105,156,175,178,194  
Studies evaluating pathogens such as Pseudomonas aeruginosa, Salmonella 
enterica, and S. aureus have identified important virulence genes by comparing 
serotypes of either less virulent or avirulent strains.176,195,196 Fowler et al. 
demonstrated significant association between specific clonal complexes (CC) and 
severity of infection in S. aureus. Among 371 S. aureus strains from diverse clinical 
settings, CC5 and CC30 were significantly associated with hematogenous 
complications such as endocarditis, septic arthritis, and vertebral osteomyelitis.175 
Gill et al. evaluated the association between the presence of specific genes among 
230 S. aureus clinical isolates and clinical outcome using array comparative 
genomic hybridization. Clinical outcomes were classified as “uncomplicated” (e.g., 
uncomplicated bacteremia or SSTI) and “complicated” (e.g., bacteremia with 
hematogenous complications). The investigators identified a total of 226 genes 
that were associated with severity of infection; 51 were more frequent and 175 less 
frequent in the complicated infection group.194 
While the above studies demonstrated the association between CC or 
presence and absence of genes with S. aureus clinical manifestations, these 
methods might have limited discriminatory power to detect higher resolution 
genetic changes. Thereby undetected and heterogenous populations may be 
broadly considered clonal. Recent advances in WGS technologies have offered 
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new opportunities to study infectious organisms at the single nucleotide level. 
However, identifying the genetic variants that explain differences in disease 
remains challenging.  
Melles et al. performed a high-throughput analysis called amplification 
fragment length polymorphism (AFLP) to analyze a collection of 900 S. aureus 
isolates from healthy nasal carriers and from invasive syndromes, including 
isolates from SSTIs and bacteremia. AFLP is a DNA technology that generates 
isolate specific DNA fingerprints by amplifying distinct subsets of genomic 
fragments by PCRs. Cluster analysis revealed sub-clusters of strains with 
differential degrees of pathogenicity. Subpopulations harboring specific toxin 
patterns were found in S. aureus strains associated with SSTIs. In contrast, 
carriage strains were found in distinct homogenous clusters, demonstrating that 
some clones are more virulent than others.180 
Although disease may follow entry of commensal S. aureus into the 
infection site through compromised epithelia, another important possibility is that 
subtle changes in the pathogen through host-pathogen interactions can precipitate 
the onset of disease. Young et al. used high-throughput genome sequencing to 
longitudinally investigate the genetic changes that occur during the transition from 
nasal carriage to a fatal blood stream infection.197 Of the recruited 360 S. aureus 
carriers, one patient developed a blood stream infection 15 months after study 
initiation. The investigators sequenced multiple colonies isolated from nasal swabs 
at different time points (early and late), and from a blood culture. All isolates were 
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MSSA, (MLST) ST-15. To compare the evolutionary changes, the investigators 
contrasted the genetic changes with two asymptomatic S. aureus carriers. The 
study found that the bloodstream S. aureus differed by only 8 SNPs from the 
original nasal carried bacteria. Half of these mutations are associated with 
truncation of proteins, including a premature stop codon in an AraC family 
transcriptional regulator. When compared with the two asymptomatic carriers, the 
analysis supported the notion that a significant excess of protein truncating 
mutations occurred on two branches separating genomes sampled from nasal 
carriage from those sampled from the invasive bloodstream infection (p=0.001). 
This study demonstrated that bacterial diversity is limited yet detected by WGS 
approaches. In addition, loss-of-function point mutations that truncate the amino 
acid sequences may play an important role in S. aureus pathogenesis.197,198 
To further the notion that minimal mutations affect S. aureus virulence, 
Kennedy et al. evaluated 10 CA-MRSA USA300 clones using comparative WGS. 
The investigators identified two MRSA clones containing 21 and 40 SNPs in the 
core genome that had significantly higher survival rates in a mouse sepsis model, 
compared with FPR3757.199 This study suggested that the difference in virulence 
or pathogenicity were due to subtle changes (SNPs) within key virulence factor 
genes and not necessarily the large scale gain or loss of entire genes.  
 Recently, Laabei et al. performed the first study to predict MRSA toxicity 
from WGS.200 A genome wide association study (GWAS) was conducted to identify 
specific loci and putative networks associated with toxicity of 90 MRSA isolates. 
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The phenotypic traits were evaluated using fibronectin and fibrinogen binding 
assays to assess the ability for strains to bind human tissues, and toxicity assays 
to evaluate the gross lytic activity. Strains were classified as low, medium, or high 
toxicity. Overall, a total of 122 SNPs and indels were identified to be associated 
with toxicity. These variants were distributed across the genome among MGE, 
genes involved in metabolism, intergenic regions, and hypothetical genes. The 
identified genetic signatures (SNPs and indels) associated with toxicity was used 
to build a class-prediction model that demonstrated a moderate degree of accuracy 
in predicting high and low toxicity strains.  
High-throughput WGS allows a more comprehensive study of the 
combination of genetic signatures, regulatory networks, and virulence factors that 
affect disease outcomes. While significant progress has been made, no studies, 
to date, have used a WGS approach in evaluating genetic signatures associated 
with clinical manifestations of staphylococcal infections. 
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CHAPTER THREE 
Specific aims 
 
Specific Aim 1 
 
To describe the clinical epidemiology, antimicrobial resistance determinants, and 
genomes of S. aureus strains in the South Texas primary care setting 
 
Sub-aim 1a: Describe the population structure of community-associated S. 
aureus isolates  
 
Sub-aim 1b: Describe the epidemiologic factors associated with multidrug-
resistant community-associated S. aureus isolates  
 
Sub-aim 1c: Apply WGS to describe the diversity and distribution of resistance 
mechanisms among community-associated S. aureus isolates 
 
Sub-aim 1d: Determine the extent to which the genotype is predictive of 
antimicrobial resistance 
 
Specific Aim 2 
 
To describe the genomic heterogeneity of S. aureus associated with colonization 
and SSTIs in the South Texas primary care setting 
 
Sub-aim 2a: Describe the epidemiologic factors associated with S. aureus 
SSTIs and nasal colonization 
 
Sub-aim 2b: Apply WGS to describe the diversity and distribution of virulence 
mechanisms among community-associated S. aureus isolates 
 
Sub-aim 2c: Identify S. aureus genetic signatures associated with SSTI isolates 
compared to colonization isolates 
 
Sub-aim 2d: Derive a predictive model to identify S. aureus isolates associated 
with SSTI 
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CHAPTER FOUR 
Materials and methods 
 
Materials and methods 
Materials and methods described in this chapter are commonly used in the 
subsequent study results chapters. Methods specific to particular parts of the 
analyses are described in more detail in the relevant chapters. 
 
S. aureus SSTI study population 
Bacterial samples and patient information used in the investigations were 
from a multisite, prospective, community-based, observational cohort study led by 
Dr. Christopher Frei in collaboration with the South Texas Ambulatory Research 
Network (STARNet), a practice based research network (PBRN) composed of 108 
urban, suburban, and rural primary care clinics distributed throughout the South 
Texas region.49,50 Health care providers at 17 STARNet clinics prospectively 
enrolled patients for this study from 2007 to 2013. Patients were eligible for study 
enrollment if they provided informed consent, were 18 years of age or older, 
presented to one of the participating clinics with a SSTI, and if their managing 
clinician suspected S. aureus. Patients were excluded if they were pregnant, 
incarcerated, or had impaired decision-making capacity. The subsequent analyses 
conducted with this study were limited to patients and samples confirmed to be S. 
aureus via microbiological testing described below. A total of 112 from a total of 
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175 S. aureus SSTI cases were selected for the analyses conducted in this 
dissertation. The University of Texas Health Science Center Institutional Review 
Board granted approval for this study. 
 Participating clinics were provided with English and Spanish informed 
consent forms, a digital camera, a portable bio-hazard container, and individually 
study kits containing a ‘clinical information card’, 15cm plastic ruler (Accu Ruler®, 
Macon, GA), and a rayon tipped wound swab (Bactiswab®, Remel, Lenexa, KS). 
Modified Stuart’s Transport Media was enclosed in a crushable ampule located at 
the base of each swab casing, near the swab collecting tip.  
 
Figure 4.1 Study Kits 
 
 
 
 
Clinicians were instructed to obtain informed consent from patients, record 
demographic and clinical information on the card, obtain a wound culture, crush 
the ampule to release the media onto the swab tip for preservation during 
transport, and capture digital pictures of the infection site. The patient data card 
included fields for the following information: gender, race, ethnicity, diabetes 
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history, health care related work history, skin infection history, height, weight, 
health insurance category, infection diameter, incision and drainage procedures 
received, antibiotics prescribed, and plans for follow up. Specimens were collected 
and stored in CryoBeads at -80°C for further testing. Additional follow-up 
information was requested to be collected via medical chart review after the initial 
clinic visit. This information included patient age at time of visit, past medical 
history (e.g., peripheral vascular disease, chronic non-infectious skin disorder, 
HIV/AIDS, cancer, actively receiving chemotherapy, immunosuppressed at time of 
visit), type of infection (e.g., furuncle, abscess, cellulitis, other), and events 
occurring within 90 days of initial clinic visit.  
 
S. aureus nasal colonization study population 
Bacterial samples and patient information were collected from a subsequent 
multisite, prospective, community-based, observational cohort study within select 
participating STARNet clinics. Health care providers prospectively enrolled 
patients for this study from March 2015 to May 2015. Patients were eligible for 
study enrollment if they provided informed consent, were 18 years of age or older, 
and if they presented to one of the participating clinics without an active infection 
(e.g., SSTI). Patients were excluded if they were pregnant, incarcerated, or had 
impaired decision-making capacity. A total of 32 colonization cases were selected 
from the 150 total screened for the analyses conducted in this dissertation. The 
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University of Texas Health Science Center Institutional Review Board granted 
approval for this study. 
 Participating clinics were provided with English and Spanish informed 
consent forms and individual study kits containing a ‘clinical information card’ 
(Appendix A), procedure guide, and a rayon tipped wound swab (BactiSwab®, 
Remel, Lenexa, KS). Modified Stuart’s Transport Media was enclosed in a 
crushable ampule located at the base of each swab casing, near the swab 
collecting tip. If the patient consented to participate in the study, the clinic staff 
were instructed to obtain a nasal swab and collect information as detailed above 
utilizing the ‘clinical information card’. To collect the nasal specimen, the cotton 
swab was inserted into the patient’s nostril (swab tip to be inserted up to 2.5cm 
from the edge of the nares) and rolled 5 times in the nares. The same swab was 
inserted into the second nostril and sampling was repeated. The swab was 
returned to its container and the ampule to release the media was crushed. These 
swabs were then collected within 24 hours for subsequent microbiological 
analyses. 
 
Bacterial identification and antimicrobial susceptibility testing 
Microbiological testing was conducted in Dr. Dallas’s Lab (UT Health 
Science Center at San Antonio), including automated antimicrobial susceptibility 
testing. Samples were plated onto pre-filled blood agar plates and incubated at 
35°C to 37°C for 24 hours, then sub-cultured to MRSA selective agar (MRSASelect 
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chromogenic agar plates; Bio-Rad Laboratories, Hercules, CA). Latex 
agglutination tests (StaphAurex®; Thermo Fisher Scientific, Lenexa, KS), and 
phenotypic screening tests (cefoxotin) were used for the identification and isolation 
of MRSA. Vitek2 AST-GP75 cards (bioMerieux, Durham, NC) were used to 
determine the susceptibility of S. aureus study isolates against ciprofloxacin, 
clindamycin, daptomycin, doxycycline, erythromycin, gentamicin, levofloxacin, 
linezolid, moxifloxacin, nitrofurantoin, rifampin, tetracycline, trimethoprim-
sulfamethoxazole, and vancomycin. Double-disk diffusion tests were performed to 
identify inducible clindamycin resistance. Mupirocin susceptibility testing was 
conducted using gradient diffusion testing (Etest, bioMerieux, Durham, NC). 
Antimicrobial minimum inhibitory concentrations (MICs) were interpreted 
according to the Clinical and Laboratory Standards Institute documents M100-S12 
(2012) and M100-S14 (2014). 
 
Sequenced isolates 
A collection of 144 single-colony isolates were selected recovered from 144 
unique patients. These were selected based on isolates with complete phenotypic 
data and patient profiles with complete demographic and epidemiologic data.  
 
DNA extraction 
 For DNA extraction, S. aureus isolates were grown in 3mL tryptic soy broth 
(TSB) shaking at 37oC for 24 hours. Overnight cultures (1.5mL) were harvested by 
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centrifugation and re-suspended with 200ul of 10 mM Tris-HCl (pH 8) and 2.5 
mg/ml of lysozyme solution (Life Technologies, Grand Island, NY). Samples were 
lysed with 200uL of MagnaPure Bacterial Lysis Buffer (Roche, Indianapolis, IN) 
and 1 mg Proteinase K (Roche, Indianapolis, IN), then incubated at 37oC for 1 hour 
then 55oC for 1 hour. Aliquots of 200uL were transferred to a MagNA Pure 96 
Instrument for automated DNA extraction using the Pathogen Universal 200 
protocol (Roche Life Science).  The quality of the extracted DNA was assessed 
with the Epoch Microplate Spectrophotometer (Biotek, Winooski, VT) and ran on 
an automated capillary electrophoresis system (Qiaxcel Advanced System; 
Qiagen, Valencia, CA). Genomic DNA was quantified using the high-sensitivity 
double stranded DNA assay on the Qubit 2.0 fluorometer (Invitrogen, Life 
Technologies, Grand Island, NY). Bacterial DNA extraction was conducted at the 
Center for Advancing Translational Technologies (South Texas Research Facility, 
UT Health Science Center at San Antonio).  
 
WGS 
Sequencing libraries were prepared using the NexteraXT DNA sample 
preparation kit (Illumina Inc., San Diego, CA) for 250bp paired end reads, following 
manufacturer’s instructions. DNA libraries were sequenced on a MiSeq 
sequencing instrument (Illumina Inc., San Diego, CA) following manufacturer’s 
instructions. Bacterial sequencing was conducted at the Genome Sequencing 
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Facility (Greehey Children’s Cancer Research Institute, UT Health Science Center 
at San Antonio). 
 
Mapping and assembly 
Sequencing data were imported and analyzed using CLC Genomics 
Workbench 8.1 (Qiagen, Redwood City, CA). Paired-end reads were mapped to a 
reference strain FPR3757 (accession NC_007793). FPR3757 (length=2,872,769 
bp) was the first USA300, ST-8 strain to be completely sequenced; this strain was 
recovered from a skin abscess, and serves as a good reference strain for our 
comparative genome analysis. Mapping was conducted using CLC read mapper. 
The parameters used included the following: mismatch cost=2; linear gap cost; 
length fraction=0.8; similarity fraction=0.8). 
 
Visualization of phylogenetic trees 
Display and manipulation of phylogenetic trees was performed using CLC 
Genomics Workbench version 8.1, Molecular Evolutionary Genetic Analysis 
(MEGA) version 7, and CSIPhylogeny v1.0a (Center for Genomic Epidemiology). 
 
Statistical analyses 
All statistical analyses were conducted on SPSS 23.0® (IBM Corp, Armonk, 
NY, USA). Statistical analyses are discussed in relevant sections in the text. 
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CHAPTER FIVE 
Specific aim 1 
 
Comparative Genomics and Antimicrobial Resistant Determinants of 
Community-Associated Staphylococcus aureus in South Texas 
 
Introduction 
Since the discovery of Staphylococcus aureus, a major challenge has been 
its remarkable ability to acquire resistance to antibiotics. The emergence of 
community-associated methicillin-resistant S. aureus (CA-MRSA) has resulted in 
an epidemic of skin and soft tissue infections (SSTI) in the U.S.2,37 Whereas 
multidrug resistance has been well described among traditional hospital-
associated methicillin resistant S. aureus (MRSA) clones, community-associated 
S. aureus clones have retained susceptibility to non β-lactam antimicrobials 
including macrolides, tetracyclines, fluoroquinolones, lincosamides, and 
trimethoprim-sulfamethoxazole. However, the increased use of these 
antimicrobials could drive the emergence of new multidrug-resistant sub clones of 
community-associated S. aureus, complicating disease management and leading 
to the development of persistent or recurrent infections. Recent reports of the 
emergence of multidrug-resistant USA300 strains have occurred in San Francisco, 
Boston, and New York City.16,74,96 The main treatment options for MRSA SSTIs 
include trimethoprim-sulfamethoxazole, clindamycin, and tetracyclines.82 The 
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emergence of resistance to these agents among USA300 strains will pose a 
challenge for treating both community- and health care-associated S. aureus 
infections.  
With rapidly advancing technology, microbial whole genome sequencing 
(WGS) is positioned to soon become a viable option in the routine clinical 
laboratory.181,182,201 WGS provides valuable information in reconstructing the 
evolution of antimicrobial resistance and has the potential to substantially increase 
the speed of antimicrobial resistance detection in the practice setting.103,184,202,203 
With the ever increasing rise of bacterial drug resistance, the need for rapid and 
reliable methods to detect its emergence and predict antimicrobial susceptibility 
has never been more imperative. 
This chapter aimed to 1) describe the population structure of community-
associated S. aureus in South Texas, 2) describe the incidence and epidemiologic 
factors associated with multidrug-resistant community-associated S. aureus 
isolates in the South Texas primary care setting, 3) use whole genome sequences 
to describe the diversity and distribution of resistance mechanisms among 
community-associated S. aureus isolates, and 4) determine the extent to which the 
genotype is predictive of resistance. 
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Methods 
 
Study setting and population:  
We performed this investigation using clinical and isolate information from 
a well-described cohort of patients with S. aureus SSTI or nasal colonization in the 
South Texas primary care setting. Details of this cohort have been described 
previously.49 Briefly, this study was conducted in collaboration with ten clinics 
within the South Texas Ambulatory Research Network (STARNet), a practice-
based research network (PBRN) composed of 108 urban, suburban, and rural 
primary care clinics distributed throughout the South Texas region, from 2007 to 
2015.  
 
Microbiological analysis:  
Samples were plated onto pre-filled blood agar plates and incubated at 
35°C to 37°C for 24 hours, then sub-cultured to MRSA selective agar (MRSASelect 
chromogenic agar plates; Bio-Rad Laboratories, Hercules, CA). Latex 
agglutination tests (StaphAurex®; Thermo Fisher Scientific, Lenexa, KS), and 
phenotypic screening tests (cefoxotin) were used for the identification and isolation 
of MRSA. Vitek2 AST-GP75 cards (bioMerieux, Durham, NC) were used to 
determine the susceptibility of S. aureus study isolates against ciprofloxacin, 
clindamycin, daptomycin, doxycycline, erythromycin, gentamicin, levofloxacin, 
linezolid, moxifloxacin, nitrofurantoin, rifampin, tetracycline, trimethoprim-
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sulfamethoxazole, and vancomycin. Double-disk diffusion tests were performed to 
identify inducible clindamycin resistance. Mupirocin susceptibility testing was 
conducted using gradient diffusion testing (Etest, bioMerieux, Durham, NC). 
Antimicrobial minimum inhibitory concentrations (MICs) were interpreted 
according to the Clinical and Laboratory Standards Institute document M100-S14 
(2014). Multidrug resistance was defined as non-susceptibility to at least three of 
the following antimicrobials or antimicrobial classes: aminoglycosides, macrolides, 
clindamycin, fluoroquinolones, trimethoprim-sulfamethoxazole, tetracycline, and 
mupirocin.204 
 
DNA sequencing and analyses: 
DNA extraction was conducted on the MagNA Pure 96 Instrument for 
automated DNA extraction using the Pathogen Universal 200 protocol (Roche Life 
Science).  The quality of the extracted DNA was assessed with the Epoch 
Microplate Spectrophotometer (Biotek, Winooski, VT) and ran on an automated 
capillary electrophoresis system (Qiaxcel Advanced System; Qiagen, Valencia, 
CA). Genomic DNA was quantified using the high-sensitivity double stranded DNA 
assay on the Qubit 2.0 fluorometer (Invitrogen, Life Technologies, Grand Island, 
NY). Sequencing libraries were prepared using the NexteraXT DNA sample 
preparation kit (Illumina Inc., San Diego, CA) following manufacturer’s instructions. 
DNA libraries were sequenced on a MiSeq sequencing instrument (Illumina Inc., 
San Diego, CA) following manufacturer’s instructions. 
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Sequencing data were imported and analyzed using CLC Genomics 
Workbench 8.1 (Qiagen, Redwood City, CA). Paired-end reads were mapped to a 
reference strain FPR3757 (accession NC_007793). FPR3757 was the first 
USA300, ST-8 strain to be completely sequenced; this strain was recovered from 
a skin abscess, and serves as a good reference strain for our comparative genome 
analysis.102 The Fixed Ploidy Variant Detection tool was used to identify single 
nucleotide polymorphisms (SNPs) and Indels and Structural Variants tool was 
used to identify insertions and deletions. Local realignment was performed to 
improve mapping in areas around insertions and deletions using an algorithm 
described by Homer et al.205 SNPs were included in analyses if that position 
contained at least 12 high-quality reads and 90% or more of them supported an 
alternate allele different from the FPR3757 reference.  
For comparative genome evaluation, SNPs were used as a measure of 
genetic pairwise distances between strains. A SNP matrix was generated using 
the Reference Sequence Alignment based Phylogeny builder (REALPHY: 
http://realphy.unibas.ch/fcgi/realphy). The output consisted of 53,840 positions per 
genome. The SNP matrix was uploaded onto MEGA7 and CLCGenomics 
Workbench 8.5.1 for phylogenetic analyses. Phylogeny was inferred using 
neighbor joining and the maximum likelihood method based on the Jukes-Cantor 
model with 500 bootstrap replicates. Consistent with previous literature, clusters 
of strains were indicated by bootstrap values of >70% for maximum likelihood and 
neighbor joining analyses.74  
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Multilocus sequence typing (MLST) was determined from the sequence 
data by extracting the sequence at the specific loci of the seven housekeeping 
genes using the CLCGenomics Workbench 8.5.1 and the S. aureus MLST scheme 
(www.pubmlst.org; downloaded November 2015). Isolates were considered to be 
USA300 if they were ST8 and the PVL genes, as previously validated.21,206 
Mobile genetic elements (MGEs) were detected in silico. Sequence reads 
were assembled de novo into contigs and were used to determine the presence 
and absence of MGEs. The assembled contigs were screened with PlasmidFinder 
to identify circular and integrated plasmids using a subset of replicon sequences 
from 139 fully sequenced plasmids associated with S. aureus.207 
  
Resistome:  
To assemble the resistome, the presence and absence of known 
antimicrobial resistance genes were identified using the ARG-ANNOT (Antibiotic 
Resistance Gene-ANNOTation) database followed by manual searching for 
chromosomal genes with amino acid variants.208 The E-value cutoff was set at 1 
e-100. The genetic elements and accession numbers associated with susceptibility 
among the S. aureus isolates are listed in Table 5.1 and 5.2. In cases where 
multiple genes map at the same location of the assembly, the best match gene 
based on percentage identity was retained. 
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Table 5.1 Genes associated with S. aureus antimicrobial resistance 
 
Antibiotic Gene Resistance Mechanism Accession No. 
Erythromycin msr(A) 
mph(C) 
Erythromycin resistance efflux protein 
(macrolide and streptogramin B resistant 
phenotype) 
Phosphotransferase inactivates macrolide 
antibiotic 
CP003194 
AF167161 
 
Erythromycin and 
Clindamycin 
ermC 
ermA 
ermB 
ermT 
rRNA adenin N-6-methyltransferase 
rRNA adenin N-6-methyltransferase 
rRNA adenin N-6-methyltransferase 
23S rRNA methylase 
HE579068 
BA00018.3 
AB699882.1 
HF583292 
Gentamicin aacA-aphD 6’-aminoglycoside N-acetyltransferase/ 
2”-aminoglycoside phosphotransferase 
FN433596.1 
Penicillin blaZ Class A beta-lactamase BX571856.1 
Methicillin mecA Low-affinity PBP2 BX571856.1 
Tetracycline tet(38) 
tet(K) 
tet(L) 
tet(M) 
Putative transport system protein 
MFS tetracycline efflux pump 
MFS tetracycline efflux pump 
Ribosomal protection protein 
FN433596 
FN433596 
HF583292 
CP002643 
Trimethoprim dfrA 
dfrC 
dfrG 
Trimethoprim-sensitive dihydrofolate 
reductase (insensitive dihdrofolate reductase) 
CP002120 
Vancomycin vanA Low affinity peptidoglycan precursor AE017171.1 
 
 
 
 
 
Table 5.2 Chromosomal genes with amino acid variants 
 
Antibiotic Gene Amino Acid Substitution Accession No. 
Ciprofloxacin gyrA 
grlA 
 
grlB 
S84L, E88K, G106D, S85P, E88G, E88L 
S80F, S80Y, E84K, E84G, E84V, D432G, Y83N, 
A116E, I45M, A48T, D79V, V41G, S108N 
R470D, E422D, P451S, P585S, D443E, R444S 
BX571857.1 
 
Rifampin rpoB A473T, A477D, A477T, A477V, D471G, D471Y, 
D550G, H481D, H481N, H481Y, I527F, I527L, 
I527M, ins 475H, ins G475, L466S, M470T, N474K, 
Q456K, Q468K, Q468L, Q468R, Q565R, R484H, 
S463P, S464P, S486L, S529L 
BX571857 
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Discrepancy investigation:  
Discrepancies were defined as discordance between susceptibility results 
using Vitek 2 and predicted genotypic susceptibility. Discrepancies were 
investigated using gradient diffusion testing (Etest, bioMerieux, Durham, NC). 
Concordance was defined as agreement between susceptibility results from Vitek 
2 or gradient diffusion with genotype. The Food and Drug Administration (FDA) 
guidelines on antimicrobial susceptibility devices were used to calculate rates of 
major and very major errors for genotypic susceptibility predictions for each 
antimicrobial tested. Major errors (ME) occur when the phenotypic result (Vitek 2) 
is susceptible and the genotypic prediction is resistant. Very major errors (VME) 
occur when the phenotypic result (Vitek 2) is resistant but the genotypic prediction 
is susceptible. The sensitivity, specificity, positive predictive value, and negative 
predictive values of the WGS genotypic prediction were determined. Table 5.3 lists 
the equations used. 
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Table 5.3 Equations for calculation of ME, VME, sensitivity and specificity 
 
A. Phenotype and genotype 2x2 table 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
B. Equations 
 
 
 
 
 
 
 
 
 
 
 
ME=major errors; VME=very major errors; PPV=positive predictive value; 
NPV=negative predictive value 
 
 
 
Antimicrobial Susceptibility 
Phenotype  
Resistant Susceptible 
G
e
n
o
ty
p
e
 
Resistant a b 
Susceptible c d 
Outcome Equation 
 
ME 
 
     a     
    a+b+c+d 
 
 
VME 
 
     c     
    a+b+c+d 
 
 
Sensitivity 
 
     a     
    a+c 
 
 
Specificity 
 
     d     
    b+d 
 
 
PPV 
 
     a     
    a+b 
 
 
NPV 
 
     d     
    c+d 
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Statistical Analyses:  
Statistical analyses were performed using SPSS 23.0® (IBM Corp, Armonk, 
NY, USA). Chi-square test or Fisher’s Exact test was used for dichotomous or 
categorical variables. Student’s t test or Wilcoxon rank sum test was used for 
continuous variables. The institutional review boards at UT Health Science Center 
San Antonio and University Health Systems approved the study. 
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Results 
Multilocus sequencing typing of S. aureus  
We sequenced 144 S. aureus isolates (112 from SSTIs and 32 from nasal 
colonization) recovered from 144 patients presenting to a STARNet primary care 
clinic.  Seventy-one strains were MRSA and 73 were MSSA. All MRSA isolates 
belonged to the ST8 clonal group (Figure 5.2). The majority (45%) of MSSA also 
belonged to ST8. Other MSSA strain types included: ST5, ST6, ST12, ST15, ST25, 
ST30, ST45, ST59, ST97, ST121, ST188, and ST1159. Four isolates had 
undefined MLST designations.  
 
Figure 5.2 Multi-locus sequence typing of S. aureus isolates 
 
 
MRSA=methicillin resistant S. aureus; MSSA=methicillin susceptible S. aureus 
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SNP-based phylogeny of S. aureus in South Texas 
To estimate the population structure, sample reads were mapped onto a 
single core reference genome, FPR3757. One-hundred and twenty three isolates 
had sufficient coverage for the analyses. We identified a total of 53,840 SNP sites 
compared to the reference sequence FPR3757. After excluding MGEs, the strains 
differed by an average of 3,548 SNPs (range 15 to 47,574). Based on the neighbor 
joining method, the isolates fell into 4 general groupings (Figure 5.3). The first 
group comprised only of ST8 isolates that grouped very tightly with FPR3757, 
differing by an average of 160 SNPs (range 15-1,215).  Approximately 70% of the 
isolates clustered in Group 1 including a number of MSSA ST8 isolates. Group 2 
encompassed two branches that were both similarly distant to the reference strain: 
one group comprised of mainly ST5 strains, which are known to be predominantly 
HA-MRSA strains, the other group was more heterogeneous without a common 
clone type. The third group comprised of a few strains that were found to be closely 
related to ST59. The fourth group comprised mainly of ST45 and ST30 MSSA 
strains.  
To provide another validation of the population structure, an approximate 
maximum likelihood tree was generated based on the similar alignment (Figure 
5.4). With 500 resamples, approximately 65% of the branches had over 0.50 
bootstrap supports. There were some secondary clusters (bootstrap support >0.70 
and congruent with neighbor joining tree) that were mostly clonal, and were 
separated mostly MLST clonal types.  
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Figure 5.3 SNP-based phylogenetic analyses of S. aureus strains 
A. B. 
 
 
 
 
SNP based phylogenetic analysis.  (A) Radial phylogenetic tree mapping the 
isolates based on the concatenated SNP distances. Green ring (group 1) primarily 
ST8 clustered tightly with reference FPR3757. Blue rings (group 2) comprised of 
two groups similarly distant to FPR3757. Purple ring (group 3) comprised of 3 ST59 
isolates. Orange ring (group 4) comprised of ST30 and ST45 isolates. (B) Zoomed-
in view of group 1 cluster comprised of ST8 isolates. 
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Figure 5.4 Maximum-likelihood phylogenetic tree of S. aureus strains 
 
 
 
 
Nodes supported by maximum-likelihood and neighbor joining bootstrap analysis 
are indicated by the yellow colored circles. Numbers at each node represent 
bootstrap values. 
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To evaluate the concordance of traditional MLST typing and WGS data, the 
MLST strain types were mapped onto the WGS phylogenetic tree (Figure 5.5). In 
this collection, isolates with the same MLST type predictably clustered into the 
same branch. Although isolates sharing the same ST cluster together, the high 
resolution of WGS demonstrated that the distance between individual isolates 
within each cluster varied from relatively close to more distant. This may suggest 
that the close clusters represent successful lineages that have undergone recent 
clonal expansion, whereas the distantly-related clades may represent rarer, less 
successful lineages. 
 
Figure 5.5 SNP-based phylogenetic analysis and MLST 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Multilocus strain types were computationally mapped onto the phylogenetic tree. 
The colored outer ring denotes the MLST type. MLST=multilocus sequence type. 
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To identify whether particular strains clustered together by geographic 
region, the location of the practice site was mapped onto the WGS phylogenetic 
tree. The MLST and phylogenetic analysis revealed that specific clones were not 
necessarily specific to particular geographic locations (Figure 5.6), with the 
exception that all S. aureus strains from Bulverde, TX were ST59.  
 
 
 
 
Figure 5.6 Geographic epidemiology of community-associated S. aureus strains 
in South Texas 
 
A.                                                   B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Phylogenetic cladogram with the outer colors coded by the location of the 
clinics. (B) Proportion of multi-locus sequence types by zip code.  
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Antimicrobial resistance determinants of S. aureus: 
The antibiograms of one hundred and forty three isolates (32 nasal isolates 
and 111 SSTI isolates) were analyzed. None of the strains were resistant to 
vancomycin, linezolid, daptomycin, or rifampin. Table 5.4 displays the 
concordance of phenotype and genotype. Genetic determinants were specifically 
isolated within specific clades on the phylogenetic tree (Figure 5.7). Notably, the 
presence of drug resistance differed substantially between ST8 isolates and the 
remainder of the sample, with methicillin resistance having the most marked 
difference. The presence of resistance determinants for aminoglycosides, 
tetracycline, mupirocin, and trimethoprim occurred infrequently and primarily only 
among ST8 isolates. 
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Table 5.4 Comparison of whole genome detection of antimicrobial resistance determinants and phenotype 
 
 
S=susceptible; R=resistant; VME=very major errors; ME=major errors; PPV=positive predictive value, NPV=negative 
predictive value. Sensitivity, specificity, PPV, and NPV are shown as percentages. 
 
 
 
 Phenotype: susceptible Phenotype: resistant Error Rate (%)  
Sensitivity 
 
Specificity 
 
 
PPV 
 
NPV 
  Genotype  Genotype 
Antibiotic # S S R # R S R VME ME 
Ciprofloxacin 87 78 7 56 3 53 2.1 4.9 95 90 85 96 
Clindamycin 133 133 0 10 0 10 0 0 100 100 100 100 
Erythromycin 70 62 8 73 3 70 2.1 5.6 96 88 90 94 
Gentamicin 141 141 0 2 0 2 0 0 100 100 100 100 
Mupirocin 140 140 0 3 1 2 0.7 0 67 100 100 99 
Oxacillin 71 67 4 72 2 70 1.4 2.8 97 93 93 97 
Rifampin 143 143 0 0 0 0 0 0 n/a 100 n/a 100 
Tetracycline 141 141 0 2 0 2 0 0 100 100 100 100 
Trimethoprim 139 139 0 4 1 3 0.7 0 75 100 100 99 
Vancomycin 143 143 0 0 0 0 0 0 n/a 100 n/a 100 
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Figure 5.7 Distribution of antimicrobial resistance determinants 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phylogeny of S. aureus strains based on concatenated SNP distances from 
reference genome FPR3757. Nodes are marked in red for multidrug-resistant 
isolates (phenotypically resistant to 1 antibiotic in > 3 classes). The presence 
of drug resistance determinants are indicated in concentric rings around the 
phylogenetic tree. The two clades with multidrug-resistant S. aureus in South 
Texas were among ST8 and ST30.  
 
 
 
 
 
 
PEN (blaZ) 
METH (mecA) 
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ERY (ermC) 
ERY (msr) 
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ST8 
ST30 
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Epidemiological features of multidrug resistance 
Approximately 31% (45) of the isolates were multidrug-resistant. Most 
multidrug-resistant isolates were ST8 (91%); one isolate was an ST30, one isolate 
was ST121, and 2 with unknown ST designations (Figure 5.6). Approximately 42% 
of ST8 strains were multidrug-resistant. A higher proportion of SSTI isolates were 
multidrug-resistant isolates compared to colonizing isolates (91% vs 9%; p<0.05). 
Notably, there was no significant difference in prior antibiotic exposures between 
cases with multidrug-resistant isolates compared to non-multidrug-resistant 
isolates (17% vs. 14%; p=0.60) (Table 5.5). Other features associated with 
multidrug-resistant isolates included African American race (p<0.01) and history of 
prior skin infections (p=0.05).  
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Table 5.5 Characteristics of patients with multidrug-resistant compared to non-
multidrug-resistant community-associated S. aureus strains 
 
 
Characteristic Overall 
n = 143 
MDR 
n = 45 
No MDR 
n = 98 
p 
Mean age, yrs. (±SD) 41 (±14) 43 (±12) 41 (±13) 0.46 
Gender     
     Male 72 (50%) 25 (56) 47 (48) 0.39 
Race/Ethnicity      
     African American 8 (6) 6 (13) 2 (2) 0.01* 
     Hispanic 111 (78) 34 (76) 77 (79) 0.67 
Diabetes 40 (28) 14 (31) 26 (27) 0.57 
Obese (BMI ≥ 30) 75 (56) 23 (53) 52 (58) 0.64 
Peripheral vascular disease 0 0 0 n/a 
Chronic non-infectious skin disorder 1 (1) 0 (0) 1 (2) 1.00 
HIV 0 0 0 n/a 
Cancer 0 0 0 n/a 
Chemotherapy 0 0 0 n/a 
Provides Healthcare to Others 5 (4) 1 (2) 4 (4) 1.00 
MRSA Phenotype 72 (50) 33 (73) 40 (41) <0.01* 
Site – SSTI (vs nasal colonization) 111 (78) 41 (91) 70 (71) <0.01* 
Prior SSTI 31 (22) 12 (27) 19 (19) 0.33 
Prior antibiotic history 19 (13) 5 (11) 14 (14) 0.60 
Prior MRSA infections 3 (3) 3 (7) 0 (0) 0.05* 
MDR=multidrug-resistant; yrs.=years; SD=standard deviation; BMI=body mass index; 
MRSA=methicillin resistant S. aureus; SSTI=skin and soft tissue infection; (*) indicates 
statistical significance.  
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Plasmid characterization 
On average, the isolates carried ~3 plasmids (range 0 to 6). The occurrence 
of pUSA300-like plasmids (e.g., pUSA02 and pUSA03) was rare and was only 
detected in 2 ST8 isolates. However, we identified other plasmids that were 
widespread. In the case for pSJH101 (rep 16), its rep genes were detected in 
strains belonging to different lineages (ST8, ST5, ST59, ST45, and ST30). This 
supports the notion of the transferring of MGEs and resistance genes among 
different S. aureus clonal lineages. Three MRSA isolates were resistant to 5 
antimicrobial classes including β-lactam, fluoroquinolones, erythromycin, 
clindamycin, and tetracycline harboring plasmids resembling pSJH901, pSJH101, 
pKH14, pE5, SAP101A, and pMSSA476 (Appendix C). One MSSA ST121 isolate 
was found to be resistant to erythromycin, clindamycin, tetracycline, and 
trimethoprim-sulfamethoxazole harboring plasmids resembling pSJH901, 
pSJH101, and pMSSA476.   
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Multidrug-resistant S. aureus by geographic region 
When evaluating geographic clustering, we found more than half of the 
multidrug-resistant isolates clustered within the Inner West Side of San Antonio, a 
predominantly Hispanic and African American community with household incomes 
significantly below state average (Figure 5.8). However, the rate of multidrug-
resistant strains (among areas with > 2 isolates) was disproportionately higher 
(50% of isolates in this geographic region were multidrug-resistant) in the 
Northwest side of San Antonio, the location of the South Texas Medical Center 
(Figure 5.9).  
 
Figure 5.8 Count of multidrug-resistant S. aureus strains by geographic region 
 
 
 
Colors of the circles indicate zip codes that multidrug-resistant S. aureus strains 
were collected from and the size of the circles represent the count of multidrug-
resistant strains. 
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Figure 5.9 Proportion of multidrug-resistant S. aureus strains by geographic 
region 
 
The size of the circles represent the count of S. aureus isolates from each region.  
Proportion of multi-drug resistance S. aureus strains in each region is depicted in 
colors: orange=multidrug resistant and pink=non-multidrug resistant strains. 
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Resistome of community-associated S. aureus  
This section describes the distribution of antimicrobial resistance 
determinants as well as the extent the WGS data correlate with standard 
antimicrobial susceptibility testing. 
 
Oxacillin. Seventy three isolates (49%) were identified as MRSA by initial 
phenotypic testing. The very major error rate was 1.4% and the major error rate 
was 2.8%. The sensitivity and specificity were 97% and 93%, respectively. The 
mecA gene was not detected in 2 isolates that were oxacillin resistant in initial 
phenotypic testing. On repeat testing, both isolates were susceptible to oxacillin 
(Table 5.6). The mecA gene was detected in 4 oxacillin-susceptible isolates in 
initial phenotypic testing. Two of these isolates tested resistant while 2 isolates 
remained susceptible upon repeat testing. Isolates harboring the mecA gene were 
ST-8 (70) and unknown (4).  
 
Ciprofloxacin. Fifty six isolates (39%) were ciprofloxacin resistant by initial 
phenotypic testing. The very major error rate was 2.1% (3/143) and the major error 
rate was 4.9% (7/143). The sensitivity and specificity were 95% and 90%, 
respectively. All 3 very major errors were susceptible on repeat testing. Four of the 
7 major errors were resistant on repeat testing. Fifty-three of the isolates that 
predicted to be resistant by genotype had the amino acid substitution S84L in gyrA, 
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and were only found among USA300 strains. This finding is explored in more detail 
in the following section. 
 
Erythromycin and Clindamycin. Seventy three isolates (52%) were erythromycin 
resistant by initial phenotypic testing. The very major error rate was 2.1% (3/143) 
and major error was 5.6% (8/143). The sensitivity and specificity were 96% and 
89%, respectively. Upon repeat testing, all 3 very major errors and 8 major errors 
aligned with the genotype. Of the 70 isolates that were confirmed erythromycin 
resistant, 10 isolates were clindamycin resistant. Of these isolates, 4 had inducible 
resistance by D-test and contained only the ermA. The 6 clindamycin resistant 
isolates without inducible resistance contained both the ermC and msrA genes. 
The 63 isolates that were resistant to erythromycin but susceptible to clindamycin 
only contained the msrA gene. There were no errors observed for clindamycin. 
Isolates harboring ermC and msr were only distributed among ST-8 strains, while 
ermA was primarily found in ST-30 strains. 
 
Gentamicin. Two ST-8 strains (1 MRSA and 1 MSSA) were gentamicin resistant 
by phenotypic testing. There were no errors observed based on the presence or 
absence of aacA(6’)-aphD(2’). The presence or absence of other putative 
aminoglycoside resistance determinants including aadD, ant(6)-Ia, aph(3’)-III, and 
spc were not correlated with gentamicin resistance in this cohort.      
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Tetracycline. Two isolates were tetracycline resistant by phenotypic testing. There 
were no errors observed based on the presence or absence of tetK. Both 
tetracycline-resistant strains had an elevated doxycycline MIC of 4 mg/L 
(considered phenotypically resistant according to EUCAST). The presence or 
absence of the efflux gene tet38 was not correlated with tetracycline resistance in 
this collection.      
 
Vancomycin. Vancomycin resistance was not identified in this collection of isolates 
by either phenotypic or genotypic testing. While the specificity was 100%, the 
sensitivity could not be estimated due to the lack of vanA among the isolates.  
 
Trimethoprim. Four isolates (2.8%) were resistant to trimethoprim by phenotypic 
testing. The very major error rate was 0.7% and no major errors were detected. 
The sensitivity and specificity were 75% and 100%, respectively. The one very 
major error tested susceptible upon repeat testing. 
 
Mupirocin. Two isolates (2.1%) displayed mupirocin resistance by initial 
phenotypic testing. One isolate harbored the mupA gene and displayed high level 
mupirocin resistance (MIC>516 µg/mL). One isolate displayed low-level mupirocin 
resistance (MIC=32 µg/mL) and contained a mutation in the native ileS gene. 
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Table 5.6 Discrepancy testing of whole genome detection of antimicrobial resistance determinants and phenotype  
 
Very Major 
Errors 
Isolate  Initial Phenotype Repeat 
Phenotype 
Genotype Resolved 
Cipro I5 R 0.125 S No gyrA or grlA mutation detected Y 
 I23 R 0.94 S No gyrA or grlA mutation detected Y 
 I39 R 0.125 S No gyrA or grlA mutation detected Y 
Erythromycin B23 R 0.125 S No erm or msrA gene detected Y 
 I7 R 0.125 S No erm or msrA gene detected Y 
 I17 R 0.125 S No erm or msrA gene detected Y 
Oxacillin B23 Oxacillin MIC>4 (R) Cefoxitin Screen (+)  0.5 S No mecA gene detected Y 
 I7 Oxacillin MIC>4 (R) Cefoxitin Screen (+)  0.25 S No mecA gene detected Y 
Trimethoprim B23 R 0.04 S No dfrA, dfrG, or dfrB mutation detected Y 
Major Errors 
Cipro A8 S > 32 R gyrA mutation detected Y 
 I7 S 8 R gyrA mutation detected Y 
 I17 S 6 R gyrA mutation detected Y 
 I42 S 16 R gyrA mutation detected Y 
Erythromycin B30 S 32 R msr gene detected Y 
 C11 S 32 R msr gene detected Y 
 I5 S 48 R msr gene detected Y 
 I11 S 24 R msr gene detected Y 
 I21 S 64 R msr gene detected Y 
 I23 S 64 R msr gene detected Y 
 I24 S 48 R msr gene detected Y 
 J17 S 32 R msr gene detected Y 
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Table 5.6 Discrepancy testing of whole genome detection of antimicrobial resistance determinants and phenotype  
 (Continued) 
 
Oxacillin A8 Oxacillin MIC<0.25 (S) Cefoxitin Screen (-)  64 R sub 
colonies 
mecA gene detected Y 
 C11 Oxacillin MIC=1 (S) Cefoxitin Screen (+)  1 S mecA gene detected N 
 I5 Oxacillin MIC<0.25 (S) Cefoxitin Screen (-)  1 S mecA gene detected N 
 I11 Oxacillin MIC=0.5 (S) Cefoxitin Screen (-)  32 R sub 
colonies 
mecA gene detected Y 
MIC=minimum inhibitory concentration 
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Fluoroquinolone resistance among USA300 
To explore the association of role of antimicrobial resistance determinants 
in the evolution of S. aureus, the presence and absence of specific resistance 
mechanisms were mapped onto the WGS phylogenetic tree. The phylogeny of S. 
aureus strains revealed that strains containing the mutation that confers 
fluoroquinolone resistance within the gyrA (leu84ser) gene clustered among 
USA300 strains in the ST8 cluster (Figure 5.10a). When evaluating the population 
structure of USA300 strains, the strains broadly clustered within two major clades 
based on the presence of fluoroquinolone resistance (Figure 5.10b). This is 
consistent with prior studies suggesting that fluoroquinolones might have further 
promoted the clonal expansion of USA300.74,209 However, whether the 
fluoroquinolone resistant strains are replacing the non-resistant types remains yet 
to be investigated. 
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Figure 5.10 Fluoroquinolone resistance among S. aureus 
 
A. 
 
 
B. 
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Figure 5.10 Fluoroquinolone resistance among S. aureus (continued) 
A. Radial tree of the chromosomal mutation gyrA conferring fluoroquinolone 
resistance (presence of chromosomal mutation marked in red). B. Maximum 
likelihood tree of USA300 S. aureus strains. Strains with the presence of 
chromosomal mutation marked in red and absence in blue. Adjacent to the tree is 
a heatmap of the presence of the mecA gene (presence=green; absence=purple) 
and the arginine catabolic mobile element (presence=red; absence=orange). 
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Discussion 
The emergence of multidrug-resistant S. aureus strains in outpatients could 
complicate disease management and contribute to development of persistent or 
recurrent community-associated MRSA infections. While multidrug resistance has 
been reported in different regions in the U.S., the magnitude of resistance among 
community-associated S. aureus infections in South Texas were unknown.  
This study identified that multidrug resistance among community-
associated S. aureus strains has emerged in South Texas. Approximately one-
third of S. aureus isolates were multidrug-resistant. The majority of the multidrug-
resistant strains were USA300 (ST8, PVL-positive). This study suggests that the 
USA300 lineage has potential to overcome the fitness cost of multidrug 
resistance.93 Approximately 10% of the isolates were carrying resistance 
mechanisms for trimethoprim-sulfamethoxazole, clindamycin, or tetracyclines, 
which are considered first line treatments against potential CA-MRSA SSTIs. 
Currently, culture and antimicrobial susceptibility testing for presumed S. aureus 
SSTIs is infrequently practiced in the outpatient setting. Our findings underscore 
the growing importance of microbial culture and antimicrobial resistance detection 
practices in the outpatient setting to minimize risk for treatment failures and 
inappropriate antimicrobial exposures.  
This investigation identified African American race and geographic areas of 
San Antonio associated with a higher proportion of multidrug resistance S. aureus. 
While several studies have reported that African American race is a risk factor for 
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MRSA infections,24,210,211 this is the first study to observe that this population may 
also be at increased risk for acquiring multidrug-resistant S. aureus strains. 
Notably, there was no significant difference in prior antibiotic exposures between 
cases with multidrug-resistant isolates compared to non-multidrug-resistant 
isolates. This indicates that multidrug-resistant strains are likely being transmitted 
person to person or antimicrobial resistance determinants are being directly 
acquired from other bacteria. The density of multidrug-resistant S. aureus was 
geographically highest in the Northwest side of San Antonio, the location of the 
South Texas Medical Center. Consistent with other studies, this indicates the 
possibility of direct acquisition of resistance determinants from multidrug-resistant 
health care-associated MRSA strains.22,43-45,118 Further studies are needed to 
determine the causes of these potential racial and geographical disparities, and 
the role hospitals play in the spread of multidrug-resistant S. aureus strains back 
into the community.  
The phylogeny of S. aureus strains revealed that strains containing the 
mutation that confers fluoroquinolone resistance within the gyrA (leu84ser) 
clustered only among USA300 strains. When evaluating the population structure 
of USA300 strains, we identified the strains clustered within two major clades 
based on the presence of fluoroquinolone resistance. This is consistent with recent 
studies in various geographic regions in the U.S. Previous epidemiological studies 
have associated increased fluoroquinolone use with the rise of CA-MRSA 
incidence rates.74,209 Because fluoroquinolones are not considered an appropriate 
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treatment option against S. aureus infections, this highlights the potential collateral 
damage of antibiotic use. The selective pressures of gyrA mutations among 
USA300 S. aureus strains requires further exploration.  
This study described the predictive patterns of antimicrobial resistance 
determinants based on genetic mechanisms most commonly observed among 
community-associated S. aureus isolates. The final results demonstrated a high 
level of concordance. After considering the findings from discrepancy testing, the 
overall VME and ME were 0% and 1.4%, respectively. This is comparable with the 
error rates for current phenotypic methodologies including the Vitek 2 and the 
Phoenix automated microbiology systems.212,213 Moreover, the error rates are 
within the acceptable limits set by the FDA for susceptibility testing methods 
(VME<1.5% and ME<3%).  
Almost all of the initially observed discrepancies were resolved by repeat 
phenotypic testing. Interestingly, all VMEs were rectified with subsequent 
discrepancy testing that aligned to the genotype. This indicates the importance of 
potential lab errors that might contribute to observed phenotypic variation 
including, inoculum density, temperature conditions, contamination, media, 
labeling, and material storage. Most MEs were resolved after repeat phenotypic 
testing. The MEs were from the detection of oxacillin resistance. The mecA gene 
was detected while phenotypically displaying susceptibility to oxacillin (MIC < 1 
ug/mL). By definition, MRSA strains have an oxacillin MIC of ≥4 ug/mL or harbor 
the mecA gene.214 However, the majority of S. aureus strains display 
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heteroresistance. Phenotypically oxacillin susceptible and mecA positive S. aureus 
strains have been increasingly reported.215-217 The clinical significance and 
approach to these strains remain unclear. While some investigations have shown 
that these strains might be responsive to β-lactam, others have demonstrated that 
β-lactams might lead to inducible resistance during treatment leading to treatment 
failure.218  
Over the last decade, significant advances have been made with next 
generation sequencing technology. Current sequence times have been reported 
to be as short ~24 hours with sequencing costs as low as $65 for an isolate.181,182 
As run times, sequencing costs, and high technical requirements continue to 
decline, WGS may be a promising tool for resistance prediction in S. aureus. 
However, there are great hurdles that need to be overcome before this technology 
can be applied. Despite the promising concordance of genotype and phenotype of 
antimicrobial resistance determinants in these studies, WGS will not be employed 
to replace AST for S. aureus in the near future for several reasons. First, WGS 
remains prohibitively expensive and may be less sensitive to culture or PCR when 
applied directly to clinical samples. Currently, phenotypic AST (e.g., automated 
broth-culture methods or disc diffusion) remains faster and cheaper. Second, there 
are major challenges for in silico resistance detection. When dealing with mixed 
samples, a technical barrier is in assigning which pathogen a plasmid-mediated 
resistance gene belongs. Furthermore, the presence of antimicrobial resistance 
determinants without phenotypic expression highlights the need for additional 
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gene expression data for select genes. Continued advancement in metagenomics 
and transcriptomics using single cell sequencing might help overcome these 
barriers. Importantly, to determine the reliability of these genotypic predictions in 
the clinical setting, particularly regarding novel resistance mechanisms, ongoing 
investigation and establishment of a central publicly available database is required. 
Several antimicrobial resistance databases exist including: Antibiotic Resistance 
Genes Database,219 Resfinder,188 and the Comprehensive Antibiotic Resistance 
Database.220 However, these databases are neither exhaustive nor regularly 
updated, and do not allow the detection of point mutations in chromosomal target 
genes associated with resistance. Therefore, analyses using these tools are 
extremely time consuming and involve multiple layers of analyses. The challenge 
is to develop a robust tool that is easily accessible to clinicians without 
bioinformatics knowledge. One such potential platform in its beginning stages has 
been recently described.193 
 
Limitations: 
 There were several limitations to this study. First, the epidemiological data 
were limited to reveal important transmission networks. The geographic 
associations were limited to the locations of the clinics that served the patients and 
not specific household addresses. In addition, this study is inherent to sampling 
bias from the participating clinics. The low or absent level of resistance to certain 
antibiotics in this collection prohibited the ability assess predictions. 
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CHAPTER SIX 
Specific aim 2 
 
Genomic heterogeneity and prediction of Staphylococcus aureus skin and 
soft tissue infections  
 
Introduction 
S. aureus is a major human pathogen and a global public health issue. It is 
considered an opportunistic pathogen as it asymptomatically colonizes its host but 
can occasionally cause diseases that range in severity from relatively minor skin 
and soft tissue infections (SSTI) to life-threatening cases of pneumonia and 
endocarditis.37 S. aureus typically exists as a commensal and colonizer of human 
skin and mucosa. Approximately 12-30% of individuals are persistent S. aureus 
carriers and 30% are intermittent carriers of S. aureus.163,167,221  Nasal colonization 
by S. aureus has been established as one of the most important risk factors for 
invasive infections.72,160,164,168,177,197,222-224 In a prospective study, Ellis et al. found 
a higher risk (relative risk 3.1, 95% CI 1.5-6.5) for nasal carriers of MRSA to acquire 
a CA-MRSA infection (i.e., cellulitis, abscess).172 Recent studies have identified 
that 70-90% of the colonized strain belonged to the same S. aureus clonal type as 
the strain involved in the skin infection.91,225 However, the pathogenetic 
mechanisms of why certain strains remain sole colonizers while some go on to 
produce SSTIs are unclear.  
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The advances of WGS techniques have offered new insights into S. aureus 
diversification during asymptomatic carriage and disease. Previous studies have 
suggested that the intra-host evolution from asymptomatic carriage to subsequent 
bloodstream infection may be driven by minimal genetic differences to discriminate 
pathogenic strains and sole colonizing strains.197 However, the genetic differences 
in pathogens during carriage and SSTIs have yet to be clearly established. In 
addition, host features and clinical context are likely to be important factors that 
have not yet been studied in conjunction with genomic investigations. Studies to 
better understand the ecology, pathogenesis, and epidemiology of S. aureus nasal 
carriage and its comparison to skin infections are needed to develop targeted 
preventative measures.  
The identification of specific variants that might be associated with S. 
aureus pathogenicity can be performed using a technique called genome-wide 
association study (GWAS). GWAS has been broadly used in human genetics to 
identify single nucleotide polymorphisms (SNPs) associated with complex 
diseases, ranging from cancer to mental health.226,227 This procedure compares 
SNPs across a population including individuals with and without the disease and 
aims to report SNPs enriched in the disease cases but absent in the healthy 
controls as potential risk factors. Bacterial GWAS allows researchers to link 
individual elements of the genotype including core genes, mobile genetic 
elements, and SNPs, to specific phenotypes.228-230 While this technique among 
bacteria remains relatively novel, it has been successfully performed using 
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Campylobacter,231 S. aureus,184,200 and Streptococcus pneumoniae.232 This 
approach gives an opportunity to investigate the molecular mechanisms of SSTI 
pathogenicity down to single nucleotide changes. Ultimately, this high resolution 
insight into pathogenicity mechanisms might contribute to the foundation for future 
applications of genome sequencing in predicting the severity of S. aureus 
infections in clinical settings and surveillance studies. 
Herein we sought to 1) describe the epidemiologic factors associated with 
S. aureus SSTIs and nasal colonization in the South Texas primary care setting, 
2) use whole genome sequences to describe the diversity and distribution of 
virulence mechanisms among community-associated S. aureus isolates, 3) 
conduct a bacterial GWAS to identify S. aureus genetic signatures associated with 
SSTI isolates compared to colonization isolates, and 4) derive a predictive model 
for SSTI.  
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Methods: 
 
Study setting and population:  
We performed this investigation among a well-described cohort of patients 
with SSTIs in the primary care setting.  Details of this cohort have been described 
previously.49 Briefly, this study was conducted in collaboration with fourteen clinics 
within the South Texas Ambulatory Research Network (STARNet), a practice-
based research network composed of 108 urban, suburban, and rural primary care 
clinics distributed throughout the South Texas region, from 2007 to 2015. Patients 
were eligible for study enrollment if they provided informed consent, were 18 years 
of age or older, and presented to one of the participating clinics with an SSTI. 
Healthcare providers collected wounds sample and patient information from each 
patient (e.g., demographics, infection characteristics, clinical information). Patients 
who presented to these clinics without an SSTI were assessed for colonization and 
were surveyed for demographic and clinical information. This study was reviewed 
and approved by the Institutional Review Board of UT Health Science Center at 
San Antonio and University Health Systems, San Antonio. 
 
Bacterial isolates:  
We selected 112 isolates of community-associated S. aureus from the 
wounds of patients presenting with SSTIs and 32 S. aureus nasal colonization 
isolates from patients without SSTIs for whole genome sequencing. 
 95 
Microbiological analysis:  
Samples were plated onto pre-filled blood agar plates and incubated at 
35°C to 37°C for 24 hours, then sub-cultured to MRSA selective agar (MRSASelect 
chromogenic agar plates; Bio-Rad Laboratories, Hercules, CA). Latex 
agglutination tests (StaphAurex®; Thermo Fisher Scientific, Lenexa, KS), and 
phenotypic screening tests (cefoxotin) were used for the identification and isolation 
of MRSA. Vitek 2 AST-GP75 cards (bioMerieux, Durham, NC) were used to 
determine the susceptibility of S. aureus study isolates against ciprofloxacin, 
clindamycin, daptomycin, doxycycline, erythromycin, gentamicin, linezolid, 
mupirocin, rifampin, tetracycline, trimethoprim-sulfamethoxazole, and 
vancomycin. Double-disk diffusion tests were performed to identify inducible 
clindamycin resistance. Antimicrobial minimum inhibitory concentrations (MICs) 
were interpreted according to the Clinical and Laboratory Standards Institute 
document M100-S14 (2014).  
 
DNA sequencing and analyses: 
Bacterial DNA was extracted on the MagNA Pure 96 Instrument for 
automated DNA extraction using the Pathogen Universal 200 protocol (Roche Life 
Science). The quality of the extracted DNA was assessed with the Epoch 
Microplate Spectrophotometer (Biotek, Winooski, VT) and ran on an automated 
capillary electrophoresis system (Qiaxcel Advanced System; Qiagen, Valencia, 
CA). Genomic DNA was quantified using the high-sensitivity double stranded DNA 
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assay on the Qubit 2.0 fluorometer (Invitrogen, Life Technologies, Grand Island, 
NY). Sequencing libraries were prepared using the NexteraXT DNA sample 
preparation kit (Illumina Inc., San Diego, CA) following manufacturer’s instructions. 
DNA libraries were sequenced on a MiSeq sequencing instrument (Illumina Inc., 
San Diego, CA) with 250-base paired-end reads. 
 Sequencing data were imported and analyzed using CLC Genomics 
Workbench 8.1 (Qiagen, Redwood City, CA). Paired-end reads were mapped to 
reference strain FPR3757 (accession NC_002952). FPR3757 was the first 
USA300, ST-8 strain to be completely sequenced; this strain was recovered from 
a skin abscess, and serves as a good reference strain for our comparative genome 
analysis.102 Local realignment was performed to improve mapping in areas around 
insertions and deletions using an algorithm described by Homer et al.205 The Fixed 
Ploidy Variant Detection tool was used to identify single nucleotide polymorphisms 
(SNPs) and Indels and Structural Variants tool was used to identify insertions and 
deletions.  
Isolates with coverage levels > 15x were included in the SNP analysis. An 
in silico SNP validation was performed to assess SNP frequency with varying 
coverage levels. Sequentially smaller sequence lists were randomly generated for 
a select isolate. Next, the aforementioned mapping and variant calling pipelines 
were run with the lower coverage subsets (Table 6.1). We identified that > 15x 
coverage detected > 94% of quality SNPs.  
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Table 6.1 In silico SNP validation 
 
Read 
Subsets 
No of 
Reads 
Average 
Coverage 
Total SNPs % SNPs 
Identified 
100% 641775 25 68 100% 
90% 577545 21 68 100% 
80% 513323 19 67 99% 
70% 449226 18 65 96% 
60% 385327 14 64 94% 
50% 320916 12 61 90% 
 
 
For comparative genome evaluation, SNPs were used as a measure of 
genetic pairwise distances between strains. A SNP matrix was generated using 
the Reference Sequence Alignment based Phylogeny builder (REALPHY: 
http://realphy.unibas.ch/fcgi/realphy) and inferred on PhyML. The alignment was 
uploaded onto MEGA7 and CLCGenomics Workbench 8.5.1 for phylogenetic 
analyses. Phylogeny was inferred using neighbor joining and maximum likelihood 
method based on the Jukes-Cantor model with 500 bootstrap replicates. 
Multilocus sequence typing (MLST) was determined from the sequence 
data by extracting the sequence at the specific loci of the seven housekeeping 
genes using the CLCGenomics Workbench 8.5.1 and the S. aureus MLST scheme 
(www.pubmlst.org; downloaded November 2015). 
 To assemble the virulomes, the presence of known virulence genes were 
detected using local blast against the S. aureus VirulenceFinder v1.5 database. 
The database contained 194 virulence genes classified as exoenzymes, host 
immune evasion, and toxins.  
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Genome-wide association analysis: 
GWAS aims to discover variants occurring over the genome that could, in 
isolation or in combination, lead to a particular trait or an unfortunate phenotype 
such as a disease. The basic premise of GWAS is a case-control study to 
statistically analyze the genetic differences between two populations: unaffected 
(controls) vs. affected individuals (cases). We conducted a case-control 
association analysis on a set of 30 colonizing isolates and 31 SSTI isolates to 
identify SNPs that were significantly associated with clinical syndrome. 
Significance levels were corrected for multiple tests using the false discovery rate 
(FDR) procedure. An FDR threshold of 10% was used to indicate significance. 
GWAS is sensitive to bias due to population structure, leading to false positives. 
To account for population stratification, we performed a hierarchical clustering 
approach to estimate the population structures.229 Next, we performed a second 
series of tests on specific variants conditioned on the results of the population 
structure using the Cochran-Mantel-Haenszel test.232 We estimated the impact of 
the population structure in the reduction of false positive associations using the 
genomic inflation factor. The inflation factor is a parameter defined as the ratio of 
observed distribution of the chi statistic to the expected median.233 A high inflation 
factor generally indicates a high rate of false positives biased by influence of 
underlying population structure. 
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Statistical analyses: 
Descriptive statistics were used to describe patient characteristics and the 
genetic profile of the bacterial isolates. The Chi-square test or Fisher’s Exact test 
was used for dichotomous or categorical variables. The Student’s t test or 
Wilcoxon rank sum test was used for continuous variables. An alpha level of 0.5 
was used to detect statistical significance. Statistical analyses were performed 
using SPSS 23.0® and CLC Genomics Software 7.0 (Qiagen, Valencia, CA).  
 
Predictive modeling: 
The standard approach to GWAS is based on univariate analyses and does 
not directly account for correlations among explanatory variables or provide 
predictive risk models.31 These limitations can be addressed by advanced 
multivariate statistics or machine learning techniques. To build a predictive model 
for SSTI, we used a Random Forest method using SPSS 18.0® Modeler (IBM 
Corp, Armonk NY).228-230,234 Random Forest is an ensemble machine learning 
method, which constructs many decision trees used to classify a new instance by 
the majority vote.234,235 Each decision tree node uses a subset of variables 
randomly selected from the whole original set of variables. Each tree uses a 
different bootstrap sample data. For the model, we included SNPs, indels, and 
clinical features detected in the univariate models. Importance scores for each of 
the variables for distinguishing the phenotypes were generated. The model was 
run using the parameters (bin=10 and ntree=100). In the Random Forest 
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approach, the initial cohort is divided into “in bag” and “out-of-bag” samples. The 
in-bag sample is created using random sampling with replacement from the initial 
cohort, creating a sample equivalent in size as the initial cohort. The out-of-bag 
sample is composed of un-sampled data from the initial cohort, and included one-
third of the initial cohort. The out-of-bag cohort served as an internal validation 
cohort for the model derived using the “in-bag” sample. The proportions of accurate 
predictions of phenotypes were reported.  
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Results 
 
Clinical and epidemiological features of patients with S. aureus SSTI and 
colonization 
The clinical characteristics of the individuals with S. aureus SSTIs and nasal 
colonization are shown in Table 6.2. Overall, the cohort had an average age of 41 
years (SD + 13), approximately half were male, and most were Hispanic/Latino 
(78%). A significantly higher proportion of nasal carriers reported being healthcare 
providers (p<0.01) while a significantly higher proportion of SSTI patients reported 
having a history of a prior skin infection (p=0.05). All other characteristics were 
similar between the two groups.  
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Table 6.2 Characteristics of patients with community-associated S. aureus SSTI 
compared to S. aureus nasal colonization 
 
Characteristic SSTI 
n = 112 
Colonization 
n = 32 
OR (95% CI) P 
Mean age, yrs. (±SD) 41 (±13) 41 (±13)  0.59 
Male  56 (50%) 17 (53%) 0.90 (0.49-1.67) 0.76 
Race/Ethnicity       
     Black 6 (5%) 2 (6%) 0.88 (0.26-3.05) 1.00 
     Hispanic 85 (76%) 27 (84%) 0.65 (0.27-1.55) 0.31 
Diabetes 31 (28%) 10 (31%) 0.88 (0.46-1.68) 0.69 
Obese (BMI ≥ 30)  61 (55%) 18 (56%) 0.95 (0.51-1.75) 0.86 
Weight > 110 kg 26 (23%) 5 (16%) 1.48 (0.62-3.55) 0.36 
Peripheral vascular disease 0 0 n/a  
Chronic skin disorder 1 (0.9%) 0 1.02 (0.98-1.06) 1.00 
HIV 0 0 n/a  
Cancer 0 0 n/a  
Chemotherapy 0 0 n/a  
Healthcare provider 1 (0.9%) 4 (12.5%) 0.25 (0.15-0.44) 0.01* 
History of skin infection 28 (25%) 3 (9%) 2.65 (0.87-8.13) 0.05* 
Prior Antibiotics within 90days 14 (13%) 5 (16%) 0.82 (0.36-1.87) 0.77 
SSTI= skin and soft tissue infection; OR=odds ratio; CI=confidence interval; yrs.=years; 
SD=standard deviation; BMI=body mass index; HIV=human immunodeficiency virus. (*) 
indicates statistical significance. 
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Heterogeneity of S. aureus SSTI and colonizing strains 
We sequenced 144 S. aureus isolates (112 from SSTIs and 32 from nasal 
colonization) recovered from 144 patients presenting to a STARNet primary care 
clinic. We found significant differences in the distribution of strain-types between 
strains isolated from nasal carriers and those isolated from SSTIs (Figure 6.1). A 
significantly higher proportion of the SSTI strains were ST8 compared to carrier 
strains (83% vs 16%; p<0.01). Comparatively, a significantly higher proportion of 
carrier strains were ST30 (8% vs. 0%, p<0.01), ST45 (16% vs. 2%; p<0.01), and 
ST5 (22% vs 4%; p<0.01) compared to SSTI strains. 
 
Figure 6.1 Multi-locus sequence typing of S. aureus isolates from SSTIs and 
nasal colonization 
 
SSTI=skin and soft tissue infection 
ST8
Unknown
ST5
ST59
ST45
ST15
ST188
ST121
ST12
S. aureus SSTI isolates (n=112)
ST30
ST5
ST8
ST45
ST188
ST6
ST15
ST25 ST97
ST1159
S. aureus colonization isolates (n=32)
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SNP-based phylogenetic analysis and genomic diversity of S. aureus SSTI and 
colonizing strains 
A genome wide phylogenetic analysis was conducted based on the SNPs 
in the core genomes of 61 S. aureus isolates. Overall, the strains differed by an 
average of 16,090 SNPs from the reference FPR3757. There were 5 main clusters. 
The first cluster comprised of mostly ST-8 SSTI isolates (Figure 6.2). Clusters 2 
and 4 comprised of all colonizing isolates, and clusters 3 and 5 contained both 
SSTI and colonizing isolates. The majority of the SSTI isolates (in clusters 1, 3, 
and 5) clustered closely with the reference FPR3757 and had an average of 4,469 
SNPs when compared to the reference. Comparatively, the nasal colonization 
strains were more divergent from the reference, with an average of 28,100 SNPs. 
To assess how the clinical phenotypes are distributed across the genetic variability 
that exists within this collection of isolates, we mapped the phenotype onto a 
phylogenetic tree based on the genome sequences of these isolates, showing the 
distribution of SSTI and colonizing phenotypes across the genotypes as well as 
some clustering. 
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Figure 6.2 SNP-based phylogenetic analyses 
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SNP analysis of ST8 strains involved in colonization compared to SSTIs 
We conducted a SNP analysis comparing ST8 nasal colonization strains 
and SSTI strains. Within group SNPs were identified if the variants were present 
in at least 70% of the samples with the phenotype. When compared to the 
reference genome, there were 79 overlapping SNPs among ST8 S. aureus SSTI 
and colonization isolates (Figure 6.3). There were 25 unique SNPs, of which 24 
were among the colonization strains. Of these 24 SNPs, 9 were nonsynonymous, 
4 were synonymous, and 11 occurred in intergenic regions. Notably, 3 of the 
nonsynonymous changes occurred in loci associated with antimicrobial activity 
including gyrA, parC, and an antibiotic transport protein (SAUSA300_rs13825). 
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Figure 6.3 Venn diagram comparing SNPs of ST8 S. aureus isolates involved in 
colonization versus SSTI 
 
 
 
 
 
 
 
 
 
 
 
SSTI=skin and soft tissue infection; SNPs=single nucleotide polymorphisms 
Blue indicates SSTI isolates and purple indicates colonization isolates. Within group SNPs 
were identified if the variants were present in at least 70% of the samples. There were a 
total 79 overlapping SNPs and 25 unique SNPs between the S. aureus isolate groups 
when compared to the reference genome, FPR3757.  
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Virulome 
All S. aureus isolates contained an average of 43 virulence genes tested. 
There were no differences in the number of virulence genes harbored among S. 
aureus SSTI isolates compared to colonization isolates (43 vs. 42; p=0.69). Overall 
frequencies of virulence genes are shown in Table 6.3. Common virulence genes 
detected across the isolates included aur (100%), hlb (98%), hlgB (98%), scn 
(94%), hlgA (92%), hlgC (90%), sak (90%), lukE (85%), lukD (83%), and splA 
(81%). Less than 10% of the isolates tested carried sed (7%), sej (7%), ser (7.0%), 
tst (6%), seb (4%), sel (2%), sec3 (1%), and edin (1%). While the invasiveness of 
S. aureus was thought to largely depend on the carriage of a battery of virulence 
factors, in our study we found that number of virulence genes was not associated 
with pathogenicity.  
The distribution of some virulence genes, especially enterotoxin genes 
(sea, sep, seb, sed, seg, sei, sej, sek, sem, sen, seo, seq, ser, seu), were 
correlated with different S. aureus lineages (Table 6.3).There were differences in 
the carriage of certain adhesion factors including splA, splB, splE. The carriage 
of pvl genes were identified only among ST8 strains and in one ST121 strain. 
There were no differences in the carriage of gamma hemolysins across the 
different lineages. The tst gene was only found among nasal colonizing strains 
belonging to ST30. These differences in the carriage rates of virulence genes 
among different ST isolates suggest that different S. aureus lineages associated 
with SSTIs have specific patterns of virulence genes.  
 109 
Table 6.3 Virulence genes by multilocus sequence strain types 
Virulence 
Factor 
Overall ST8  
(n=98) 
ST5 
(n=11) 
ST30 
(n=8) 
ST45 
(n=7) 
Unkwn 
(n=6) 
ST15 
(n=3) 
ST59 
(n=2) 
ST188 
(n=3) 
ST1159 
(n=1) 
ST121 
(n=1) 
ST97 
(n=1) 
ST6 
(n=1) 
ST12 
(n=1) 
ST25 
(n=1) 
Adhesions (n, %) 
aur (n, %) 144 (100) 98 (100) 11 (100) 8 (100) 7 (100) 6 (100) 3 (100) 2 (100) 3 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
fnbA 142 (98.6) 96 (98) 11 (100) 8 (100) 7 (100) 6 (100) 3 (100) 2 (100) 3 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
fnbB 134 (93) 91 (98) 11 (100) 8 (100) 4 (57) 6 (100) 3 (100) 2 (100) 3 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
clfA 144 (100) 98 (100) 11 (100) 8 (100) 7 (100) 6 (100) 3 (100) 2 (100) 3 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
clfB 144 (100) 98 (100) 11 (100) 8 (100) 7 (100) 6 (100) 3 (100) 2 (100) 3 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
icaA 144 (100) 98 (100) 11 (100) 8 (100) 7 (100) 6 (100) 3 (100) 2 (100) 3 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
icaD 144 (100) 98 (100) 11 (100) 8 (100) 7 (100) 6 (100) 3 (100) 2 (100) 3 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
splA 117 (81.3) 89 (90.8) 11 (100) 0 0 6 (100) 3 (100) 0 3 (100) 1 (100) 0 1 (100) 1 (100) 1 (100) 1 (100) 
splB 108 (75.0) 80 (81.6) 11 (100) 0 0 5 (83.3) 3 (100) 0 3 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
splE 112 (77.8) 88 (89.8) 0 8 (100) 0 5 (83.3) 3 (100) 0 3 (100) 1 (100) 0 1 (100) 1 (100) 1 (100) 1 (100) 
splF 121 (84.0) 89 (90.8) 11 (100) 8 (100) 0 6 (100) 3 (100) 0 3 (100) 1 (100) 0 1 (100) 1 (100) 1 (100) 1 (100) 
Host immune evasins (n, %) 
ACME 58 (40) 54 (55.1) 0 0 0 4 (66.7) 0 0 0 0 0 0 0 0 0 
edinA 1 (0.7) 0 1 (9.7) 0 0 0 0 0 0 0 0 0 0 0 0 
edinB 1 (0.7) 0 0 0 0 0 0 0 0 0 0 0 0 0 1 (100) 
sak 125 (86.8) 87 (88.8) 11 (100) 5 (62.5) 7 (100) 6 (100) 0 0 3 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
scn 135 (93.8) 93 (94.9) 11 (100) 4 (50.0) 7 (100) 6 (100) 3 (100) 2 (100) 3 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
Toxins (n, %) 
Enterotoxin 14 (9.7) 2 (2.0) 8 (72.7) 0 3 (42.9) 0 0 0 0 0 0 0 0 0 1 (100) 
hla 142 (98.6) 96 (97.9) 11 (100) 8 (100) 7 (100) 6 (100) 3 (100) 2 (100) 3 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
hlb 141 (97.9) 95 (96.9) 11 (100) 8 (100) 7 (100) 6 (100) 3 (100) 2 (100) 3 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
hlgA 133 (92.4) 88 (89.8) 11 (100) 8 (100) 7 (100) 6 (100) 2 (66.7) 2 (100) 3 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
hlgB 141 (97.9) 96 (98.0) 11 (100) 8 (100) 7 (100) 5 (83.3) 3 (100) 2 (100) 3 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
hlgC 130 (90.3) 88 (89.8) 11 (100) 8 (100) 7 (100) 3 (50) 2 (66.7) 2 (100) 3 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
lukD 120 (83.3) 93 (94.9) 11 (100) 0 0 5 (83.3) 3 (100) 0 3 (100) 1 (100) 1 (100) 0 1 (100) 1 (100) 1 (100) 
lukE 123 (85.4) 96 (98.0) 11 (100) 0 0 5 (83.3) 3 (100) 0 3 (100) 1 (100) 1 (100) 0 1 (100) 1 (100) 1 (100) 
lukF 92 (63.9) 87 (88.8) 0 0 0 4 (66.7) 0 0 0 0 1 (100) 0 0 0 0 
lukS 78 (54.2) 74 (75.5) 0 0 0 3 (50) 0 0 0 0 1 (100) 0 0 0 0 
sea/sep 14 (9.7) 2 (2.0) 2 (18.8) 4 (50.0) 0 1 (16.7) 0 0 2 (66.7) 1 (100) 0 0 1 (100) 1 (100) 0 
seb 6 (4.2) 0 0 0 0 0 0 0 2 (66.7) 0 0 0 0 1 (100) 1 (100) 
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Table 6.3 Virulence genes by multilocus sequence strain types (continued) 
Virulence 
Factor 
Overall ST8  
(n=98) 
ST5 
(n=11) 
ST30 
(n=8) 
ST45 
(n=7) 
Unkn 
(n=6) 
ST15 
(n=3) 
ST59 
(n=2) 
ST188 
(n=3) 
ST1159 
(n=1) 
ST121 
(n=1) 
ST97 
(n=1) 
ST6 
(n=1) 
ST12 
(n=1) 
ST25 
(n=1) 
Toxins cont’d 
sec3 2 (1.4) 1 (1.0) 0 0 1 (14.3) 0 0 0 0 0 0 0 0 0 0 
sed 10 (6.9) 2 (2.0) 8 (72.7) 0 0 0 0 0 0 0 0 0 0 0 0 
seg 29 (20.1) 1 (1.0) 11 (100) 8 (100) 7 (100) 0 0 0 0 0 1 (100) 0 0 0 1 (100) 
sei 27 (18.8) 2 (2.0) 8 (72.7) 8 (100) 7 (100) 0 0 0 0 0 1 (100) 0 0 0 1 (100) 
sej 10 (6.9) 2 (2.0) 8 (72.7) 0 0 0 0 0 0 0 0 0 0 0 0 
sek 86 (59.7) 79 (80.6) 1 (9.1) 0 0 4 (66.7) 0 2 (100) 0 0 0 0 0 0 0 
sel 3 (2.1) 2 (2.0) 0 0 1 (14.3) 0 0 0 0 0 0 0 0 0 0 
sem 28 (19.4) 2 (2.0) 10 (90.9) 8 (100) 6 (85.7) 0 0 0 0 0 1 (100) 0 0 0 1 (100) 
sen 28 (19.4) 2 (2.0) 11 (100) 8 (100) 5 (71.4) 0 0 0 0 0 1 (100) 0 0 0 1 (100) 
seo 28 (19.4) 1 (1.0) 11 (100) 8 (100) 7 (100) 0 0 0 0 0 0 0 0 0 1 (100) 
seq 90(62.5) 81 (82.7) 2 (18.8) 0 0 5 (83.3) 0 2 (100) 0 0 0 0 0 0 0 
ser 10 (6.9) 2 (2.0) 8 (72.7) 0 0 0 0 0 0 0 0 0 0 0 0 
seu 15 (10.4) 0 3 (27.3) 8 (100) 3 (42.9) 0 0 0 0 0 1 (100) 0 0 0 0 
tst 9 (6.3) 0 2 (18.8) 7 (87.5) 0 0 0 0 0 0 0 0 0 0 0 
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We compared the differences in carriage of virulence genes of SSTI and 
colonization strains among ST8 lineage (Table 6.4). The hlb gene was present in 
99% of the SSTI strains compared to 60% of the colonizing strains (p<0.01). Prior 
studies have described the well-established role of S. aureus hlb in skin 
colonization by damaging keratinocytes, in addition to its well-known hemolytic 
activity for erythrocytes.35 There were no other differences in virulence genes 
identified. 
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Table 6.4 Virulence genes among ST8 S. aureus SSTI and colonization isolates 
 
Virulence 
Factor 
SSTI 
n=93 
Colonization 
n=5 
P 
Adhesions 
aur 93 (100) 5 (100) n/a 
fnbA 91 (98) 5 (100) n/a 
fnbB 91 (98) 5 (100) n/a 
clfA 93 (100) 5 (100) n/a 
clfB 93 (100) 5 (100) n/a 
icaA 93 (100) 5 (100) n/a 
icaD 93 (100) 5 (100) n/a 
splA 84 (90.3) 5 (100) 1.00 
splB 75 (80.6) 5 (100) 0.58 
splE 82 (88.1) 5 (100) 0.69 
splF 85 (95.5) 4 (80) 0.46 
Host immune evasins 
ACME 53 (57) 1 (20) 0.17 
edinA 0 0 n/a 
edinB 0 0 n/a 
sak 82 (88.2) 5 (100) 1.00 
scn 87 (93.1) 5 (100) 1.00 
Toxins 
Enterotoxin 2 (2.2) 0 (0) 1.00 
hla 92 (99) 4 (80.0) 0.10 
hlb 92 (99) 3 (60.0) <0.01* 
hlgA 83 (89.2) 5 (100.0) 1.00 
hlgB 92 (98.9) 4 (80.0) 0.10 
hlgC 84 (90.3) 4 (80.0) 0.42 
lukD 88 (94.6) 5 (100) 1.00 
lukE 89 (95.7) 5 (100) 0.84 
lukF 84 (90.3) 3 (60.0) 0.09 
lukS 72 (77.4) 2 (40.0) 0.09 
sea/sep 1 (1.1) 1 (20.0) 0.10 
seb 0 0 n/a 
sec3 1 (1.1) 0 1.00 
sed 1 (1.1) 1 (20.0) 0.10 
seg 1 (1.1) 0 1.00 
sei 2 (2.2) 0 1.00 
sej 1 (1.1) 1 (20.0) 0.10 
sek 75 (80.6) 4 (80.0) 1.00 
sel 1 (1.1) 1 (20.0) 0.10 
sem 2 (2.2) 0 1.00 
sen 2 (2.2) 0 1.00 
seo 1 (1.1) 0 1.00 
seq 77 (82.8) 4 (80.0) 1.00 
ser 1 (1.1) 1 (20.0) 0.10 
seu 0 0 n/a 
tst 0 0 n/a 
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Genome-wide comparison of S. aureus SSTI and colonization isolates 
We compared the genomes of 31 SSTIs and 30 nasal colonization S. 
aureus isolates to identify the genetic polymorphisms associated with the clinical 
phenotype. Out of a total of 529 SNPs, we identified 18 SNPs that were 
significantly associated with SSTIs after adjustment using FDR (Figure 6.4).  
Further, 3 indels were found to be significant. These SNPs and indels were 
distributed across the genome in 8 candidate loci among mobile genetic elements 
(SCCmec and ACME), genes involved in metabolism and regulation, RNA 
modification enzymes, and in genes encoding for hypothetical proteins. Six were 
nonsynonymous, 4 were synonymous, and 11 were in intergenic regions.  
 
Figure 6.4 Manhattan plot of S. aureus SSTI genome-wide study 
 
SSTI=skin and soft tissue infection. Manhattan plot summarizes the association of whole 
genome variants with SSTIs compared to colonization S. aureus isolates as well as 
particular coding regions which showed strong associations. The y-axis represents the 
statistical significance of association for each variant in order on the genome (x-
axis).Genes with significant associations are annotated. 
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The description of these SNPs and functions of the loci is located in Table 
6.5. Hierarchical clustering analysis based on the SNP/indel proximity identified 
potential linkage disequilibrium of variants; however, many appeared to be 
independent (Figure 6.5). 
The intrinsic clonal population structure can result in high false positive rates 
in genome wide association studies.30 To estimate the population structures, we 
used a hierarchical clustering algorithm that showed 6 main clusters (Figure 6.6). 
Based on this clustering information, the Cochran-Mantel Haenszel association 
statistic was used to test for associations between SSTI and specific variants, 
conditioned on the population cluster. Adjusting for the population structure 
decreased the genomic inflation factor from 54.8 (median chi-squared 
statistic=24.9) to 2.5 (median chi-squared statistic=1.15). This decrease indicates 
a reduction in the probability of false positive rates due to population substructures. 
Out of the 21 polymorphisms previously identified, only 3 (snp425833, 
snp1568945, and ins62590^62591) remained significant after this procedure. 
Unfortunately, the limited sample size prevented us from using a more detailed 
clustering approach. One of these candidate loci (snp425833) was located in a 
gene encoding for phosphoglycerate mutase, an enzyme responsible for glycolysis 
(RS02000), which results in Glu106Asp change to the amino acid sequence. The 
second SNP was located in a gene encoding a phage portal protein (RS07655). 
The third candidate was located in an intergenic region between a transposase 
and the speG gene within the ACME unit.  
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Table 6.5 Details of significantly associated variants 
 
Position in 
reference FPR3757 
Reference base Allele Type Effect CDS in 
FPR3757 
CDS Function 
425833 A T SNV Nonsynonymous RS02000 Phosphoglycerate mutase - metabolism  
556082 T C SNV Noncoding Intergenic Flanked by a lysyl-tRNA synthetase (lysS) and 
transcriptional regulator protein, (gntR) 
1961354 C T SNV Noncoding Intergenic Flanked by alpha/beta hydroxylase and a 
hypothetical protein 
317 A G SNV Noncoding Intergenic Flanked by chromosomal replication initiator 
protein dnaA 
1994913 A - Deletion Nonsynonymous RS09905 IS1181, transposase 
658674 T G SNV Noncoding Intergenic Flanked by two hypothetical proteins 
1995031..1995081 TTTTAAAAATAG
TTCTTTAAATTAT
ATACCCACCAC
ATTTGGTGGAG
AACC 
- Deletion Noncoding Intergenic Flanked by a transposase and a transcriptional 
regulator, peroxide-responsive repressor perR 
658465 T A SNV Noncoding Intergenic Flanked by two hypothetical proteins 
658668..658672 TTTTT GAGCC MNV Noncoding Intergenic Flanked by two hypothetical proteins 
1568945 C T SNV Synonymous RS07655 Phage portal protein 
61025 G A SNV Nonsynonymous RS00265 Hypothetical protein 
658463 A T SNV Noncoding Intergenic Flanked by two hypothetical proteins 
1959504 T A SNV Noncoding Intergenic Flanked by alpha/beta hydroxylase and a 
hypothetical protein 
35970 T C SNV Synonymous RS00145 Putative transposase; K07498  
36124 G A SNV Nonsynonymous RS00145 Putative transposase; K07498  
656344..656345 AA TT MNV Nonsynonymous RS03115 Hypothetical protein 
656348 G T SNV Nonsynonymous RS03115 Hypothetical protein 
34179 T A SNV Synonymous RS00135 Ribosomal RNA large subunit methyltransferase 
H; 23S rRNA modification factors 
35817 A T SNV Noncoding Intergenic Flanked between a transposase and a 
hypothetical protein 
1354028 C T SNV Synonymous RS06705 Secretion protein 
62590^62591 - A Insertion Noncoding Intergenic Flanked between a transposase and spermidine 
N1-acetyltransferase (speG) 
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Figure 6.5 Evaluation of potential linkage disequilibrium 
 
Tree showing all SNPs and indels, with those in linkage disequilibrium clustered together 
with blue bracket. 
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Figure 6.6 Hierarchical clustering of isolates 
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Predictive modeling 
To test whether these candidate signatures can be predictive of S. aureus SSTIs, 
we built a predictive model using the set of 5 variables [3 SNPs/ins and 2 clinical 
predictors (health care provider status and history of prior skin infection)]. The 
model showed an accuracy of >88% (misclassification rate of <12%). The 
phenotype prediction rate is shown in Table 6.6. The significance of each variable 
in this model is displayed on Figure 6.7. The top influential variable was 
snp425833. 
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Figure 6.7 Random forest predictor importance 
 
 
Variables ordered by descending degree of importance in the predictive model. 
 
 
 
Table 6.6 Random Forest prediction of SSTIs 
 
Observed Predicted 
Colonization SSTI % Correct 
Colonization 26 5 84% 
SSTI 3 26 90% 
 
 
 
 
 
 
 
snp425833 
snp1568945 
ins62590^62591 
History of skin 
infection 
Health care 
provider 
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Discussion 
There has been an increase in the incidence of community-associated S. 
aureus infections worldwide.8,59,236 SSTIs are the most common manifestation of 
CA-MRSA infections; however, the molecular changes and contribution of select 
genetic features of S. aureus that facilitate its propensity to cause SSTIs has yet 
to be determined. The application of WGS captures the full extent of bacterial 
genomic variations and allows for genome-wide comparisons can potentially be 
applied to predict the pathogenicity of staphylococcal infections.237,238 In this study, 
we have described the bacterial genomic heterogeneity among S. aureus from the 
South Texas community setting associated with colonization and skin infections. 
Prior studies have described the contribution of a particular S. aureus clonal 
type to be associated with disease manifestations.2,39,77,175,176,209,211,239 Consistent 
with prior literature, we found that ST8 genotype is associated with SSTIs and that 
the nasal carriage rate of ST8 remains relatively low.91,160,163,164,225 In addition, we 
found that the CA-MRSA colonization rates (3%) are far below CA-MSSA (20%). 
This may be the nature of a combination of factors including colonization site(s) 
not evaluated (e.g. skin, nasopharynx, gastrointestinal), different risk of person-to-
person spread from infected patients or from contaminated fomites, and unique 
pathogenicity mechanisms that may bypass the hypothesis of sequential 
colonization before infection. Although our study demonstrated a significant 
association between genotype and SSTIs, it is important to note that almost all of 
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the common clonal types were found in both SSTIs and nasal colonization isolates. 
Hence, most S. aureus strains have the capacity to cause SSTIs.  
There was diversity in the distribution of virulence genes among the strain 
types. Interestingly, the nasal colonization strains carried a similar array of 
virulence genes as those strains isolated from SSTIs. This may imply that rather 
than large scale genomic changes at the gene level, higher resolution changes at 
the nucleotide level may be driving the pathogenic potential of S. aureus strains.  
With the genome sequences of both SSTI and nasal colonization strains, 
we conducted a bacterial GWAS to determine potential genetic markers down to 
the single nucleotide level associated with the pathogenicity of community-
associated S. aureus strains. We identified 22 significant SNPs, of which 3 
remained significant when population structure was considered in the model. 
Among these 3 variations, 1 non-synonymous SNP (snp425833) was found to be 
the most influential variable in the predictive model for SSTIs.  The candidate SNP 
was located in a gene encoding for phosphoglycerate mutase. Phosphoglycerate 
mutase is an important surface enzyme in glycolysis and gluconeogenesis.240 Prior 
studies have described the multiple roles of glycolytic and metabolic enzymes and 
their role in virulence characteristics.240,241 Phosphoglycerate mutase has been 
previously identified as a streptococcal cell surface plasminogen binding 
protein.242 In addition, in vitro studies have identified phosphoglycerate mutase as 
an antigen that is upregulated in staphylococcal biofilm production; Beenken et al. 
found phosphoglycerate mutase was expressed at higher levels in biofilms than in 
 122 
planktonic S. aureus.240,243 This reveals a potential novel mechanism of 
pathogenicity and transmission as biofilm formation by S. aureus is believed to 
contribute to their ability to colonize both biotic and abiotic surfaces. The functional 
role of phosphoglycerate mutase in the pathogenesis of skin infections requires 
further exploration. The second most influential site was an insertion in an 
intergenic region between a transposase and the speG gene. The speG gene in 
the arginine catabolic mobile element (ACME) unit encodes a spermidine 
acetyltransferase that allows S. aureus to evade polyamines, products involved in 
wound healing and inflammation on human tissues.144-146 The third most influential 
loci was within a gene encoding for a phage portal protein. Further work is needed 
to characterize these loci and whether it may lead to amplification or attenuation 
of S. aureus pathogenesis cascade.  
 There were several limitations to this study. First, an important limitation is 
the small sample size which may have limited the identification of significant SNPs 
or SNP-SNP interactions with lower effect sizes. Second, SNPs could represent 
variable and transient events within a bacterial species, therefore spontaneous 
mutations cannot be entirely ruled out. However, other studies have suggested 
that genomic variation between closely related bacterial strains have undergone 
selection and are not spontaneous mutations.244 Third, we identified a relatively 
high genome inflation factor suggesting that the underlying clonal population 
structure remains an issue that may lead to false positives. We attempted to 
address this confounding by conducting a series association tests conditioned for 
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the population structure; however, residual confounding may remain. While a 
within-host evolutionary study may have been more ideal to identify causality, the 
nature of this type of study was beyond the scope of this investigation, considering 
the unpredictable nature of host-pathogen interactions for the progression to 
infections.198 Further work including mutagenesis and transcriptomics will be 
needed to validate the roles of the identified candidate loci in S. aureus 
pathogenesis. Fourth, sequences were mapped onto a reference genome, 
FPR3757. A limitation is that the DNA not found in the reference strain, therefore 
other potential loci that affect pathogenicity, was not evaluated. Further, while we 
used nasal carriage as our source for colonization, other sites (e.g., groin, 
nasopharynx, perianal areas) have also been implicated in colonization and may 
involve different pathogenetic mechanisms. Lastly, when predicting the clinical 
manifestations of infection, undoubtedly, the interplay of host factors and the 
environment in addition to the pathogen will need to be accounted for. We 
attempted to address this, in part, by merging significant clinical meta-data with 
genotype in the predictive model. External validation of this prediction model with 
larger datasets and diverse lineages are required. While an important barrier for 
progress in this field has been the inability to consistently prove that specific 
bacterial virulence determinants are responsible for clinical manifestations of 
infection, we have provided one step in this direction.  
 This study described the heterogeneity of S. aureus SSTIs and nasal 
colonization isolates. While this study was exploratory and hypothesis generating 
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in its approach, it identified potential novel pathogenicity mechanisms that will 
require further functional validation. The future challenge will be to build robust 
models that convert multiscale data into information that can be used to predict 
severity of S. aureus infections to rapidly tailor precision medicine in the clinic and 
to devise new preventative strategies.  
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CHAPTER SEVEN 
Conclusions 
 
This dissertation described the diversity of S. aureus population in the South 
Texas community, identified genetic determinants contributing to antimicrobial 
resistance, and characterized potential mechanisms for pathogenicity in isolates 
from healthy carriage and SSTIs. This chapter summarizes the major findings from 
the chapters, their applications, and directions for future work. 
 
Comparative genomics and antimicrobial resistance determinants of community-
associated S. aureus in South Texas  
The evolution of community-associated S. aureus toward resistance to 
additional antibiotic classes is a major concern. This chapter demonstrated that 
multidrug resistance among community-associated S. aureus strains has emerged 
in South Texas. When evaluating epidemiological links, African Americans and a 
geographic region near a major health care setting were associated with higher 
proportions of multidrug-resistant strains. Moreover, the distribution of 
antimicrobial resistance determinants varied by clonal type. The majority of the 
multidrug-resistant strains were of the USA300 lineage. This study also reveals 
that a large proportion of the USA300 isolates sequenced are resistant to 
fluoroquinolone antibiotics. Further work to explore the selective pressures and 
role of gyrA mutations associated with fluoroquinolone resistance among USA300 
is needed. Finally, this chapter demonstrated the high level of concordance when 
comparing antimicrobial resistance determinants to the phenotypically derived 
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antibiogram. This study is the first large dataset comprised of isolates from the 
primary care setting which adds to the growing literature supporting the future 
application of WGS in the clinical setting.  
 This study raises several subsequent questions regarding the drivers of 
antimicrobial resistance among community-associated S. aureus strains. A next 
step is to conduct a longitudinal study among infection cases and their households 
to reveal the patterns of transmission, the evolution of resistance during and 
between antimicrobial treatments, role of microbial communities, and the 
environment. Furthermore, transmission studies evaluating S. aureus at the 
interface of hospital and community settings might reveal novel transmission 
networks and evolutionary pathways of the acquisition of antimicrobial resistance.  
 
Genomic heterogeneity and prediction of S. aureus SSTIs 
S. aureus is an opportunistic pathogen that commonly exists as a colonizer 
but can occasionally cause infection. The most common manifestation of 
community associated S. aureus is skin and soft tissue infections. Factors 
revealing the pathogenetic mechanisms of why some strains go on to produce 
infection could result in novel effective control methods and diagnostic models. 
This study revealed that genomic heterogeneity exists among community 
associated S. aureus isolates causing colonization and SSTIs in South Texas. 
These variations may play a role in the pathogenesis of variation in pathogenicity 
and clinical severity. Methodologically, this study adds to the very sparse literature 
on using a bacterial GWAS approach. Together, this holds great promise for 
microbial functional genomics where experiments can be systematically designed 
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to test the phenotypes followed by large-scale sequencing to draw important 
phenotype-genotype associations. 
Future work will expand on these findings toward studying the interaction 
between host and pathogen, linking genomic variation and their functional roles to 
pharmacodynamic responses, and furthering the development of using multiscale 
data to predict severity of infection among patients presenting with S. aureus 
infections. The application of WGS as a phenotypic prediction tool holds great 
potential to transform the way we manage and prevent S. aureus infections. In the 
clinical setting, WGS may be useful for deciding the course of S. aureus treatment 
at an early stage of disease. For example, a clinician may treat a highly toxic or 
resistant infection more aggressively with consideration for antimicrobials known 
to reduce toxin expression of S. aureus (e.g., clindamycin, linezolid). On the other 
hand, WGS can serve as a key tool for antimicrobial stewardship by preventing the 
use of broader-spectrum antimicrobials in patients with low toxicity and/or 
susceptible infections. Furthermore, understanding the pathogenetic mechanisms 
can lead to vaccine development and other important preventative strategies.  
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APPENDICES 
APPENDIX A: Clinical information card 
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APPENDIX B: S. aureus isolate information 
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APPENDIX C: S. aureus plasmid content 
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APPENDIX D: Loci of significant variants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variants 
FPR3757 CDS 
Annotations 
 
Amino acids 
snp425833 
snp1568945 
Variants 
FPR3757 CDS 
Annotations 
 
Amino acids 
snp62590 
Variants 
FPR3757 CDS 
Annotations 
 
Amino acids 
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